Glucocorticoid Treatment and Quality of Life in Addison’s disease by Øksnes, Marianne
Glucocorticoid Treatment and 
Quality of Life in Addison’s 
disease 
Marianne Øksnes 
Avhandling for graden philosophiae doctor (ph.d.)  
ved Universitetet i Bergen 
2014
Dato for disputas: 06.06.14 
2Learn from yesterday, live for today, hope for tomorrow. The important thing is not to 
stop questioning. 
Albert Einstein 
3Scientific environment 
This work was carried out at Department of Clinical Science, Section for 
Endocrinology, Faculty of Medicine and Dentistry, University of Bergen; in 
cooperation with Department of Medicine, section for Endocrinology, Haukeland 
University hospital, Bergen, Norway. The endocrinology research group is led by 
Professor Eystein Husebye.  
This research was funded by the European Union Seventh Framework Programme 
Grant 201167, Euradrenal. The Euradrenal is a research cooperation between adrenal 
researchers in several European countries, led by professor Eystein S. Husebye, 
University of Bergen. This work was performed in collaboration with Euradrenal 
partners in Sweden (paper II, III and IV), UK (paper I and II), Italy, Germany and 
Poland (paper II). 
The research group has also received funding from the regional Health Authorities of 
Western Norway.  
4Acknowledgements 
First of all, I would like to thank my main supervisor Kristian Løvås for encouraging 
me to enter the world of science, and for trusting me in continuing his original work. 
Kristian, you are patient, kind, wise and a wizard with words; working with you has 
been inspiring and fun. I want to express my gratitude to my co-supervisor Eystein 
Husebye; your support, knowledge and know-how has been invaluable.  
The Husebye research group has been a welcoming environment. I am especially 
grateful to Elisabeth T. Halvorsen, who has handled and administered the study 
samples in an impeccable order, always professional and positive. I would also like to 
thank Inger J. Næss for all our hours together in front of an excel-file, and for 
administrating the logistics in the best possible way during the clinical trial. I would 
like to thank my fellow phD student Paal Methlie, for constructive discussions and 
collaboration around cortisol metabolism and AUC calculations. My gratitude goes to 
Eirik Bratland, Anette Bøe Wolf, Bergithe Oftedal, Ingeborg Brønstad, Marianne 
Astor, Marianne Grytaas, Elin Theodorsen, Katerina Simunkova, Hajira Muneer, 
Alexander Hellesen, Lars Breivik, Kine Edvardsen and Elisabeth Whiteley who all 
contribute to the professionalism and positive attitude in the research group. 
Especially I am grateful to my “work-wife” and dear friend Martina Moter Erichsen; 
your enthusiasm, humour and wit continues to brighten my days. 
I want to thank all my co-authors in Norway, Sweden, UK, Germany, Italy and 
Poland; without you this work could not have been completed. Especially, I want to 
thank Sophie Bensing and Sigridur Bjørnsdottir who have been my closest 
collaborators. Our endless discussions have been both fruitful and fun. I have really 
enjoyed learning from co-author and statistician Roy Miodini Nilsen at the Centre for 
Clinical Research. I want to thank co-author Kai Triebner and Steinar S. Hustad at the 
Core Facility for Metabolomics at UiB for excellent cooperation.  
I thank present and former head of the endocrinology section, Hrafnkjell Thordarson 
and Sylvi Aanderud, for their support. I am grateful to all my colleagues at the 
5Section for Endocrinology at Haukeland University Hospital who provide a great 
work environment; Jan-Inge, Nevena, Eirik, Elinor and Grethe. Likewise, I want to
thank co-author Siri Carlsen at Stavanger University Hospital for being my good 
friend and colleague as well as the best professional travel partner I could have.
My gratitude also goes to Arne Quist Paulsen, who introduced me to the field of 
endocrinology in the best possible way.  
I have profited from the study drug and application know-how of Jannicke Wathne at 
the hospital pharmacy, and from the skills of diabetes nurse Berit Tarlebø, who has 
led the CSHI patient education and even spent some nights with the participating 
patients in Bergen. I want to thank Elisabeth Bjerkan, Torill Våge and Hilde 
Sælensminde at the Clinical Research Unit; without your cooperation the circadian 
study would not have been performed. I would like to thank Ingunn Anundskaas at 
Innovest for monitoring the clinical trial in Norway, and Bjørn Bjorvatn for 
generously providing actigraph equipment for the clinical trial.  
There can be no clinical research without the interest and efforts provided by 
participating patients. I am deeply grateful and impressed by all participants who 
spent so much of their personal time to contribute.   
Finally, I would like to thank my parents Vibeke and Terje Øksnes, who brought me 
up believing that I could do anything if I remained positive and worked hard enough. 
Your support in family logistics has also been invaluable. To my love and best friend 
Geir; thank you for always supporting and believing in me, you are my rock. To my 
beloved children Andreas, Emma and Ulrik; thank you for continuously reminding me 
that life is not always logical and that quality-of-life is much more than statistics.  
6Abbreviations 
AC:  Addisonian crisis 
ACTH:  Adrenocorticotropic hormone 
AD:  Addison’s disease 
AIRE:  Autoimmune regulator 
allo-THF: allo- tetrahydrocortisol 
APS:  Autoimmune Polyendocrine Syndrome 
AUC:  Area under the curve 
BMD:  Bone mineral density 
BMI:  Body mass index 
BSA:  Body surface area 
CA:  Cortisone acetat 
CAH:  Congenital adrenal hyperplasia 
CBG:  Cortisol binding globulin 
CRH:  Corticotropin-releasing hormone 
CSHI:  Continous subcutaneous hydrocortisone infusion 
CTX-1: C-terminal crosslinked C-telopeptide of type 1 collagen 
CVD:  Cardiovascular disease 
CYP3A4 : 6ȕ-hydroxylase  
DHEA(S): Dehydroepiandrosterone (sulphate) 
7DIF:   Differential item functioning 
DOCA: Desoxycorticosterone-acetat 
EEG:  Electroencephalogram 
EFA:  Exploratory factor analysis 
FT4:  Free T4, Free thyroxine 
GC(s): Glucocorticoid(s) 
GR(s): Glucocorticoid receptor(s) 
GH:  Growth hormone  
GRE:  Glucocorticoid responsive elements 
HbA1c: Hemoglobin A1c 
HDL:  High-density lipoprotein
HIV:  Human immunodeficiency virus 
HOMA: Homeostatic model assessment 
HPA axis: Hypothalamus-Pituitary-Adrenal axis 
HRQoL:  Health Related Quality of Life 
IFN-Ȧ: Interferon omega 
LC-MS/MS:  Liquid chromatography and sequential mass spectrometry 
LDL:   Low-density lipoprotein 
M-value: Whole-body insulin sensitivity
MR:  Mineralocorticoid receptor 
8MC1-5R: Melanocortin receptor 1-5 
MCID: Minimal clinically important difference 
MSH:  Melanocyte stimulating hormone 
NEFA: Non-esterified fatty acids 
OHC:   Oral hydrocortisone 
PAI:  Primary adrenal insufficiency 
PER1:  Period 1 gene 
PGWB: Psychological general well-being index 
PNMT: Phenylethanolamine-N-methyltransferase 
P1NP:  Procollagen type 1 N-terminal peptide
POMC: Pro-opiomelanocortine 
PRA:  Plasma renin activity 
PSI:  Person separation index 
PSQI:  Pittsburgh sleep quality index 
PTH:  Parathyroid hormone 
PVN:  Paraventricular nucleus 
QoL:  Quality of Life 
REM:  Rapid eye movement 
ROAS: Registry of Organ specific Autoimmune Diseases 
SAI:  Secondary adrenal insufficiency  
9SCC:  Side-chain cleavage enzyme 
SCN :  Suprachiasmatic nucleus  
SF-36: Short Form-36 
SHBG: Sex hormone binding globulin 
SMR:  Standard mortality rate 
SWS:  Slow wave sleep 
THE:  Tetrahydrocortisone  
THF:  Tetrahydrocortisol  
TSH:  Thyrotropin 
VAS:  Visual-analog scale  
VLCFA: Very long chain fatty acids 
WHO: Word Health Organisation 
WHR:  Waist hip ratio 
ȕ-LPH: Beta-lipotropin  
11ȕ-HSD: 11 beta-hydroxysteroid dehydrogenase 
17OHP: 17-hydroxyprogesterone 
21-OH: 21-hydroxylase 
21OHAb: 21-hydroxylase antibodies 
10
Abstract 
Addison’s disease (AD) is rare and result in lack of the adrenal hormones cortisol, 
aldosterone and adrenal androgens. Despite conventional oral replacement therapy, 
mortality is increased and Health-Related Quality-of-life (HRQoL) is reduced. 
Currently, the non-physiological circadian cortisol profile is suspected to be a major 
cause, although evidence has been lacking. Here, we aimed to develop a better tool 
for evaluating HRQoL in AD, and to investigate whether a more physiological 
circadian cortisol profile would result in benefit for AD patients. 
An AD-specific HRQoL questionnaire (AddiQoL) was developed through a multistep 
approach. After testing the original AddiQoL in 86 patients in UK, the AddiQoL was 
translated to five European languages and tested in further 615 AD patients in 
respective countries. Applying Rasch analysis, a valid and reliable 30 item AddiQoL 
was produced.  
In a randomized controlled multicenter trial with cross-over design, we compared the 
effects of three months treatment with continuous subcutaneous hydrocortisone 
infusion (CSHI) to the effects of three months treatment with conventional oral 
hydrocortisone (OHC) in 33 AD patients. The primary endpoint was the effect on 
ACTH levels. Secondary endpoints were effects on metabolism, HRQoL and sleep. 
CSHI produced a more physiological circadian cortisol biorhythm than conventional 
therapy and induced normalization of morning ACTH and cortisol levels, restoration 
of nighttime cortisol levels and changes in glucocorticoid metabolism resembling 
healthy individuals. The late night decrease in glucose seen with OHC was 
counteracted, without decreasing overall insulin sensitivity. CSHI did not 
significantly affect sleep but might have positive HRQoL effects. 
The AddiQoL development provided a valid and reliable new tool for HRQoL 
evaluation in AD. Mimicking the physiological cortisol rhythm with CSHI proved 
safe and provides a means for further improving replacement therapy in AD. 
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2. Introduction 
Normal physiology 
The adrenals
The adrenals are endocrine organs located above each kidney, consisting of a cortex 
and a medulla. The adrenal medulla consists of chromaffin cells, specialized for the 
production of the catecholamines adrenaline and noradrenaline in response to 
stimulation from the sympathetic nerve system. Although the medulla is of different 
embryonic origin and regulated independently of the adrenal cortex, medullary 
adrenaline production is dependent on cortisol production from the adrenal cortex. 
The production of adrenalin from its precursor noradrenalin is rate-limited by the 
enzyme phenylethanolamine-N-methyltransferase (PNMT), which is induced by high 
local concentrations of cortisol in the medulla; glucocorticoids (GCs) are also 
necessary for maintenance of chromaffin cells (1). 
The adrenal cortex’s characteristic architecture reflects the different hormones 
produced, each hormone being derived from cholesterol (Figure 1). The outer layer, 
zona glomerulosa, is the source of mineralocorticoids; the most important is 
aldosterone. Aldosterone is crucial for regulating water- and salt homeostasis, hereby 
regulating blood pressure. The effect of aldosterone is mediated via the 
mineralocorticoid receptor (MR); located in the kidneys, salivary glands and colon. 
Activation of the MR in the kidneys will increase urinary reabsorption of sodium and 
water, and increase excretion of potassium. Aldosterone production is regulated by 
the renin-angiotensin system, which is responsive to changes in blood pressure and 
potassium balance. Although aldosterone production is regulated independently of 
cortisol production, the MR is not aldosterone specific, and cortisol excess will result 
in stimulation of the MR producing an aldosterone-like effect (2). 
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GCs are produced in the middle cortex layer, zona fasciculata, where the principal 
hormone is cortisol. GCs have diverse and wide-spread effects, which is not 
surprising given the fact that glucocorticoid receptors (GRs) are present in virtually 
every cell type in the human body. Briefly, cortisol is important for modulation of the 
immune system, for neuron function as well as for maintaining energy metabolism 
and bone metabolism (further outlined below).  
The adrenal androgens dehydroepiandrosterone (DHEA) and androstenedione are 
produced from zona reticularis, the innermost level of the adrenal cortex. DHEA is 
further metabolized to dehydroepiandrosterone sulphate (DHEAS) in other tissues. 
Androgen production is stimulated by ACTH. Their physiological role in humans is 
still not clear as they have very little intrinsic androgen effect, and are thought to 
function as circulating pro-hormones that can be converted to active androgens in 
androgen sensitive tissues (3). The adrenals contribute 30-50% of androgens in men, 
but are responsible for 50-100% of androgens in pre- and postmenopausal women (4, 
5).  
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The Hypothalamus-Pituitary-Adrenal (HPA) axis 
Adrenal production of cortisol is under tight control of the physiological HPA axis 
feed-forward/feed-back system (Figure 2, (6)). A state of cortisol deficiency will 
stimulate the paraventricular nucleus (PVN) to secrete corticotropin releasing 
hormone (CRH), which again will stimulate the anterior pituitary to secrete ACTH. 
ACTH promotes cortisol production from the adrenals. Conversely, a state of cortisol 
sufficiency or excess will suppress CRH and ACTH, leading to lack of adrenal 
stimulation and reduction of cortisol production.  There is a delay in the positive feed-
forward cortisol response to ACTH because cortisol has to be synthesized de novo in 
the adrenal cortical cell before secretion. Cortisol exerts a negative feed-back effect 
by binding to low-affinity GRs and high affinity MRs in the brain. It has been 
suggested that the effect of MR dominates in the early nighttime when cortisol levels 
are low (to maintain low basal HPA activity), whereas the GR inhibitory effect on the 
HPA axis dominates in the morning when cortisol levels peak (to constrain HPA 
activity), although this view has recently been disputed (7, 8).  
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ACTH is derived from the Pro-opiomelanocortine (POMC) peptide produced in the 
anterior pituitary, and is enzymatically split into Ȗ-melanocyte-stimulating hormone 
(Ȗ-MSH), ACTH and ȕ-lipoprotein (ȕ-LPH) (Figure 3). ACTH and ȕ-LPH is further 
split to produce two other melanocortins; Į-MSH and ȕ-MSH. All of these 
melanocortins share a common core sequence of four amino acids, which produces 
overlap in receptor binding. In conditions characterized with high ACTH levels, ȕ-
LPH is also elevated (9). Ȗ-MSH, but not Į-MSH, is increased by stressors, and 
decreased with negative GC feed-back (10, 11).  
The recent decades have produced new insight in the melanocortin system, 
particularly after identification of the five melanocortin receptors (MC1R-MC5R). 
Activation of these receptors has diverse effects, such as immune modulation, 
lipolysis and effects on feeding behaviour and metabolism (12). The MC2R is ACTH  
specific and predominantly found in the adrenals, where stimulation will increase 
cortisol production, and in adipocytes, where in vitro studies have shown that 
activation induces lipolysis (13). The best described function of the MC1R is 
induction of melanogenesis, but the receptor is also identified in non-pigmented cells 
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(14). MC3R and MC4R are both involved in energy homeostasis and feeding (15, 16), 
and mediates the central effects of melanocortins, including neuroprotection (17). 
MC3R has additional effects on control of inflammation (18). MC5R is widely 
distributed, and has been shown to have immune modulating effect on B- and T-
lymphocytes and mast cells, and effects on exocrine secretions (19). Hence, immune 
modulating effects of melanocortins can be mediated by several of the receptors, 
although the mechanism is not fully understood. However, studies have shown that Į-
MSH can inhibit antigen stimulated T cell proliferation and inhibit production of 
proinflammatory cytokines through inhibition of a nuclear transcription factor (17).  
Glucocorticoid rhythm - circadian and ultradian 
The word circadian derives from the Latin circa (around) and dies (day), and 
physiological oscillations with 24 h periodicity are referred to as circadian rhythms. 
Oscillation of shorter duration, i.e. a few hours, is referred to as ultradian. Circadian 
rhythms control a wide range of physiological events, such as sleep, body 
temperature, feeding patter and even metabolism (20).  
In healthy subjects, cortisol levels fluctuate in a circadian manner, with nadir around 
midnight, followed by gradually increasing levels during the last part of the night 
culminating in the highest peak near awakening (21).The circadian rhythm of cortisol 
production depends on activity in the suprachiasmatic nucleus (SCN), via the PVN in 
the hypothalamus (22).  The SCN also receives input regarding light, and can adapt 
the circadian cortisol rhythm to the day/night cycle. CRH is derived mainly from the 
PVN, and act on CRH receptors in the pituitary to promote the production and 
secretion of ACTH. This effect can be potentiated by other neuropeptides, especially 
vasopressin. CRH is secreted in a circadian and pulsatile fashion, with the highest 
levels occurring during the early morning and the lowest levels during the first part of 
the night.  
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In recent years new technology has made it possible to examine the rhythm/pattern of 
the HPA axis more closely, revealing an underlying ultradian rhythm, with cortisol 
pulses approximately once per hour, preceded by pulses of ACTH (Figure 4). Every 
secretory pulse of ACTH is followed by a delayed response of cortisol (6). The 
amplitude of the pulses varies with the circadian pattern, with the highest amplitude 
before awakening. This cortisol pulse rhythm is synchronized between the blood, the 
subcutaneous tissue and the brain (23). Pulsed stimulation of the GR has also been 
shown to result in pulsed transcription of GC-responsive genes, and pulsatile 
signalling produces a different transcript when compared to constant signalling (24). 
This dynamic transcriptional system provides a sensitive mechanism for the 
maintenance of homeostasis by enabling cells to rapidly detect and respond to 
changes in circulating cortisol (6).  
Destruction of the SCN will abolish the circadian rhythm, while the ultradian rhythm 
is maintained (25). This has challenged the earlier view that also the ultradian rhythm 
is the results of a hypothalamic pulse generator. Recent studies have suggested that 
these oscillations result from a pituitary-adrenal system producing a complex feed-
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forward/feed-back system (26). It is hypothesized that the delayed feed-forward 
response in cortisol in combination with rapid GC feed-back inhibition at the level of 
the pituitary is the primary factor behind the ultradian rhythm. 
Disruption of the cortisol rhythm has been associated with various disorders, for 
example depression (27), obstructive sleep apnoea (28) and sleep disorders (29). 
Interestingly, Plat and co-workers were able to show that elevation of plasma cortisol 
in the evening when the HPA axis is normally quiescent has more deleterious 
metabolic effects than a similar elevation in the morning when the HPA axis is 
maximally activated (30), implicating that maintenance of the circadian cortisol 
rhythm is of importance also in carbohydrate metabolism. Studies have also shown 
that GCs regulate the expression of the clock gene PER1, suggesting a role for GCs in 
modulating the biological circadian clock (31-33). 
Glucocorticoid receptors  
The peripheral effects of GCs are primarily mediated through the intracellular GR. 
The concentration of GRs in a given tissue can modify the effect magnitude of 
receptor binding (34). The effect of ligand binding differs from one cell type to 
another, implicating that several mechanisms are involved in signal transduction.  
The GR belongs to the nuclear receptor family, and upon cortisol binding, the GR-
ligand complex undergoes conformational changes that result in translocation to the 
nucleus. Through interactions with GC responsive elements in the genome the 
complex functions as a transcription factor for target genes; however, multiple 
possible genomic binding sites exist (35). Access to the genome, and hence 
transcription, is also dependent on the presence of protein co-activators or repressors 
which may facilitate or hinder the GR’s access to RNA II polymerase by remodelling 
chromatin (34). In addition to the direct effect on DNA transcription, the GR also 
interacts with other non-receptor transcription factors and co-regulators through 
protein-protein interactions, which can either induce or repress transcription, 
producing another mechanism for cell-specific effects of GCs (36, 37). Finally, GCs 
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also have rapid (anti-inflammatory) non-genomic effects, although the physiology and 
function of these are still not fully understood (38, 39).  
The GR has a lower affinity for cortisol than the MR. In the brain, notably the 
hippocampus and the pituitary, GCs can also exert their effects through the MR. The 
MR has a high affinity for cortisol and has a high degree of occupancy during basal 
conditions, as the MR’s aldosterone specificity seen in the periphery is lacking due to 
the lack of 11ȕ-hydroxysteroid dehydrogenase type 2 (11ȕ-HSD2). Hence, the MR 
can maintain receptor activation throughout 1h intervals between secretory cortisol 
bursts lasting 20 minutes, whereas activation of the GR follows the ultradian rhythm 
more closely (40). Tissue differences in distribution of receptor type may therefore 
allow similar pulses to convey different information to different tissues (8). 
Glucocorticoid effects  
The widespread distribution of the GR in combination with the distribution of GC to 
virtually every tissue by the circulation enable GCs to modulate the expression of 
about ten percent of our genes, although few if any genes are exclusively controlled 
by GCs (34, 41). This is mirrored in the complex picture of GC function in the human 
body. Historically, the physiological effect of cortisol is sometimes confused with the 
effects of supra-physiological pharmacological GC doses, as there are few studies on 
GC effects during physiological sub-saturating conditions (42). Unfortunately, the 
role of GCs in maintaining homeostasis in a non-stressful situation is less clear (43).  
It was Philip Hench who incidentally discovered the anti-inflammatory effects of 
cortisone, an observation which granted him the Nobel Prize in medicine and 
physiology in 1950 (44). The GCs are now known as key players in the regulation of 
inflammation and immunity, with well-known and important immunosuppressive 
effects of pharmacological doses (45). Cytokines and other pro-inflammatory 
mediators can activate the HPA axis. The resulting increased cortisol levels will exert 
a negative feed-back by inhibiting the inflammatory process, hence constraining the 
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immune response from going overboard (38, 43, 45). Hypercortisolism in the absence 
of inflammation, i.e. Cushing syndrome or high-dose GC treatment, can cause 
immunosuppression and increase the risk of infection (45).  
High doses of GCs also have important effects on carbohydrate and lipid metabolism 
by increasing glycogen production and gluconeogenesis in the liver (46), inhibiting 
peripheral glucose uptake and increasing lipolysis. The net effect is an increase in 
insulin resistance and increased levels of glucose, that is, acting as an insulin 
antagonist, producing a diabetogenic effect with concomitant catabolism of lipids and 
proteins (47). This effect is important when the body requires rapidly available energy 
substrates to cope with a major stressor. Chronic hypercortisolism causes 
hyperglycaemia and may lead to type 2 diabetes mellitus, whereas chronic 
hypocortisolism (i.e. adrenal insufficiency) predisposes for hypoglycaemia.   
However, the influence of GCs on glucose metabolism in normal subjects in a non-
stressful situation is not fully understood, and some authors have suggested that the 
name glucocorticoid is misleading (38, 48). Thus, although cortisol may act 
synergistically with other factors to influence carbohydrate metabolism, being 
especially important in a stressful situation, the role of GCs in carbohydrate 
metabolism in the normal situation is less clear. Also, GCs act in concert with other 
hormones such as insulin, glucagon, growth hormone (GH), among others, which also 
have profound effect on carbohydrate metabolism.  
Multiple other effects of GCs are described; most of them are associated with supra-
physiological doses (47): In the skin, connective tissue and in muscle, GCs cause 
atrophy. In bone, osteoblasts are inhibited, decreasing bone formation. Also, calcium 
absorption from the intestines is reduced, resulting in elevated parathyroid hormone 
(PTH) levels and further deteriorating bone metabolism. GCs can increase blood 
pressure by several mechanisms. Synthesis of angiotensinogen is increased, the 
sensitivity to catecholamines and angiotensin II is increased in vascular smooth 
muscle and the nitric oxide mediated dilatation of endothelia is reduced. While these 
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effects are important in the event of a major stressor, chronic high endogenous or 
exogenous delivery of GC will cause hypertension. GCs also have cerebral dose- 
dependent effects. In addition to effects on sleep (29), GCs are also linked to feeding 
behaviour, cognitive function and psychiatric disturbances, depression being the most 
common diagnosis (49). 
In the later chapters of this thesis I will focus on the effects of GC in the context of 
replacement therapy rather than on effects of GCs in general.  
Glucocorticoid metabolism 
The concentration of free cortisol accounting for biological activity accounts for less 
than 5% of the total cortisol concentration (50). The half-life of circulating free 
cortisol is short, approximately 70-120 min. More than 90% of circulating cortisol is 
bound, predominantly to cortisol-binding-globulin (CBG, 70%), and to a lesser degree 
to albumin (20%) (51). CBG is saturated at 400-500 nmol/L, higher levels will 
increase the biological active free fraction rapidly (52). CBG is synthesized in the 
liver – production is enhanced by estrogens – and levels might also be elevated in 
patients with chronic active hepatitis and acute lymphatic or myeloid leukemia. CBG 
levels are reduced by GCs, and in patients with hyperthyroidism, cirrhosis and 
nephrotic syndrome (53). In AD patients, both the total and the free cortisol levels are 
reduced.  
A crucial step in the metabolism of cortisol is the interconversion of cortisol to 
cortisone, governed by the intracellular 11ȕ-hydroxysteroid dehydrogenase (11ȕ-
HSD) enzymes, and local tissue concentrations of cortisol are modulated by tissue-
specific 11ȕ-HSD. Hereby 11ȕ-HSD can modulate the magnitude of the cortisol 
response on the tissue level.  This enzyme has 2 different isoforms: 11ȕ-HSD type 1 
(11ȕ-HSD1) and 11ȕ-HSD2.   
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11ȕ-HSD1 is widely expressed in the human body and functions predominantly as a 
reductase, regenerating cortisol from the biologically inactive counterpart cortisone to 
maintain adequate activation of the GR in local tissue. 11ȕ-HSD1 activity is 
especially abundant in the liver (54), although a significant contribution from adipose 
tissue and skeletal muscle has been demonstrated (55, 56). This implies that 11ȕ-
HSD1 might modulate circulating cortisol levels (57). In healthy humans, the 
proportion of the total cortisol pool derived from 11ȕ-HSD1 mediated regeneration of 
cortisol from cortisone has been quantified to approximately 11 nmol/min when the 
adrenal cortisol production rate was 38 nmol/min (58). This suggests that the inactive 
metabolite cortisone function as a systemic GC reservoir, which can be locally 
activated when needed, in the presence of 11ȕ-HSD1 (59). Others have suggested that 
although the primary function of 11ȕ-HSD1 functions is to regenerate cortisol from 
cortisone, it may also function as a dehydrogenase, that is, promote conversion of 
cortisol to cortisone. This dual function facilitates recycling between cortisol and 
cortisone in local tissues (41, 56). 11ȕ-HSD1 activity can be stimulated by thyroid 
hormones and inhibited by growth hormone (60).  
Circulating cortisone levels in healthy people are primarily dependant on renal 11ȕ-
HSD2 activity, approximating one fifth of circulating cortisol levels (61). ACTH 
stimulation has been shown to decrease cortisone levels in addition to increasing 
cortisol levels, hence increasing the cortisol/cortisone ratio (59). This suggests that 
ACTH may modulate peripheral metabolism of cortisol by modulating 11ȕ-HSD 
activity, which might be important under stressful conditions. 
11ȕ-HSD2 provides a barrier against GC excess in tissues with high aldosterone 
sensitivity, such as the kidneys and salivary glands were 11ȕ-HSD2 inactivates 
cortisol to cortisone. In a state of GC excess, renal 11ȕ-HSD2 activity can be 
exceeded, increasing loss of cortisol in the urine and increasing the urine 
cortisol/cortisone ratio (57). 11ȕ-HSD2 genetic insufficiency or inhibition causes 
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apparent mineralocorticoid excess and hypertension due to inappropriate GC 
activation of the renal MR (62-64). 
Both cortisol and cortisone can be further metabolised by similar pathways, to 
dihydrocortisol and dihydrocortisone, respectively (Figure 5). These metabolites are 
further hydroxylated to form tetrahydrocortisol (THF) and tetrahydrocortisone (THE). 
The reduction to THF can be performed by 5Į-reductase or 5ȕ-reductase, giving rise 
to two different isoforms: THF and allo-THF. In normal subjects the 5ȕ-reductase 
dominates (THF/allo-THF 2:1). Approximately 50% of secreted cortisol appears in 
the urine as THE, THF and allo-THF (47) . Cortisol can also be metabolised to 6ȕ-
hydroxycortisol by 6ȕ-hydroxylase (CYP3A4). Normally this is a minor pathway; 6ȕ-
hydroxycortisol represents about 1% of the total metabolites in the urine. However, 
CYP3A4 can be induced by hypercortisolism and certain drugs/substances 
(anticonvulsant, rifampicin, pioglitazone, St. John’s Wart, statins, gapefruit juice), 
hence increasing the proportion of cortisol metabolized through this pathway. Some 
drugs inhibit this enzyme, but usually the degree of inhibition is small (e.g. 
clarithromycine, danazol, fluconazol, levonorgestrel, fluoxetine, diliazem, cimetidine) 
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(60). There is a large inter-individual variance in urinary excretion of 6ȕ-
hydroxycortisol, but the ratio 6ȕ-hydroxylase/cortisol can be used for estimating the 
CYP3A4 enzyme induction capacity of a drug when patients are their own controls 
(65).                                                                                                                                                         
Urine cortisol, cortisone and metabolites have been used to indirectly calculate the 
activity of cortisol metabolising enzymes. The urinary cortisone/cortisol ratio has 
been primarily used as an index for 11ȕ-HSD2 activity, the ratio of allo-THF/cortisol 
for 5Į-reductase, the ratio THF/cortisol and THE/cortisone for 5ȕ-reductase and the 
(THF + allo-THF)/THE ratio as an overall measure of 11ȕ-HSD activity (55, 66, 67). 
In healthy humans, urine free cortisone excretion is larger than free cortisol excretion, 
and the normal urinary free cortisol/cortisone ratio is around 0.54, whereas the normal 
urinary free (THF + allo-THF)/THE ratio is around 1.21 (67). In that study, urinary 
free cortisone excretion was found to be normal in patients with pituitary 
insufficiency on GC replacement therapy, whereas in patients with ACTH-dependent 
Cushing syndrome the urinary cortisone excretion and the cortisol/cortisone ratio 
were highly elevated.  
Sleep and the HPA axis 
Normally, sleep consists of cycles with light sleep (stage 1 and 2), deep sleep (3 and 
4) and rapid eye movement (REM) sleep. More time is spent in deep sleep (slow wave 
sleep, SWS) during the first part of the night, and most REM sleep occurs during the 
last part of the night. REM sleep typically appears in 90 minute cycles. Sleep structure 
can also be describes as having only 3 stages, that is REM, non-REM and stage wake 
(29). Each sleep stage is characterized by specific electroencephalographic (EEG) 
sleep waves and frequency; decreased frequency is associated with deeper sleep, and 
increased frequency with wakefulness. The sleep stages and architecture can be 
determined by polysomnography; where EEG waveform, eye movement and 
electromyography determine each sleep stage. 
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The HPA axis is implicated in influencing sleep patterns (29, 68, 69). Physiologically, 
HPA axis activity is at its lowest the first part of the night when the deepest sleep 
(SWS) occur. The gradual increase in ACTH and cortisol during the last part of the 
night coincides with lighter sleep and increasing amount of time spent in REM sleep. 
It has been suggested that awakening results in a following cortisol peak, 
superimposed on the circadian cortisol fluctuation (70). Efforts to identify isolated 
effects of CRH, ACTH and cortisol on sleep have been made, but not all have been 
consistent (71, 72). Exogenous CRH has been shown to increase EEG frequency in 
healthy males, hereby decreasing SWS and REM sleep and increasing light sleep and 
awakenings, and this effect was more pronounced during the last part of the night 
(73). Both pulsatile and continuous nocturnal cortisol infusion has been documented 
to increase SWS and reduce REM in normal controls (71). Since cortisol and CRH 
have opposite effects on SWS, it has been suggested that the observed cortisol effects 
were due to negative feedback inhibition of CRH (74). A dose-dependent cortisol 
effect has been documented; while lower levels of cortisol is thought to be necessary 
for SWS, too high levels will promote fragmentation of sleep. It has been suggested 
that this is due to the type of receptor being activated, suggesting that while low doses 
will only activate the high affinity MR and increase SWS, higher doses will also 
activate the GR, increasing light sleep fragmentation and wakefulness (29). This is 
consistent with the decreased SWS found in patients with hypercortisolism (75). 
Quality of life 
Definition 
Although the term “Quality of life” historically is relatively new, the concept has been 
known to man through centuries, through synonyms like well-being, happiness, 
having a good life, life satisfaction, etc. In the Nichomachean Ethics, Aristoteles 
(384-322 BC) wrote: Both the multitude and persons of refinement…conceive “the 
good life” or “doing well” to be the same thing as “being happy”. But what
constitute happiness (which includes well-being according to the translator Harris 
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Rackham) is a matter of dispute. Quality of life was then rarely mentioned before the 
twentieth century, although Thomas Jefferson has been cited for including the pursuit 
of happiness as an inalienable right in the United States Constitution (76). 
In 1948 the WHO declared health as: a state of complete physical, mental and social 
well-being, and not merely the absence of disease or infirmity (77). Hence, health 
professionals cannot merely focus on saving patient lives (improving quantity of life); 
restoring the well-being of the patient should also gain importance. Quality of life 
usually refers to a person’s general well-being including physical, mental and social 
aspects; but more philosophical use of the word is broader, and the term is used in a 
wide range of contexts. There are many other factors impacting how a person views 
his own well-being, including personality, environment, socioeconomic status, etc. 
Hence, the term quality-of-life is broad and ill-defined, and can be viewed in terms of 
an individual, group or large population of patients (78). In health sciences we are 
most interested in evaluating those aspects affected by disease or disease treatment. 
The term “Health Related Quality of life” (HRQoL) is used to emphasise the 
difference, which usually includes aspects concerning perception of general health 
(overall questions about how a person view his health), physical health (symptoms 
and disabilities), mental health (emotional and cognitive functioning), and sometimes 
also social well-being (the impact on their social life) (79).  
HRQoL is influenced by how a person cope with the challenge of a disease, and a 
person’s coping abilities are of course influenced by numerous factors, such as 
personality, earlier experiences or expectations, social support or influences, 
educational level and more. Therefore, it is not unexpected that two persons with the 
same objective disease burden will experience the HRQoL impact caused by the 
disease differently. Hence, HRQoL is sometimes referred to as “subjective health 
status”. Furthermore, how a person copes with a challenge over time, for instance a 
chronic disease will also influence the HRQoL scores measured later in life; this 
phenomenon is called response shift. Response shift can be described as a change in 
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the meaning of the patient’s self-evaluation (score), and is suggested to be due to 
recalibration, reprioritisation, and reconseptualisation (80). HRQoL changes can be 
underestimated if response shift is not taken into account (81), particularly when 
comparing patient scores with normative data.  
Measuring HRQoL 
So how is it possible to measure the concept of well-being, or HRQoL, in individuals 
or patient groups? The key feature of HRQoL measurement when compared to other 
clinical tests is the incorporation of patient values, judgement and preference, 
attempting to bridge the gap between the patient views and the views of researchers or 
clinicians; with the words of Galileo Galileo (1564-1642): to measure what is 
measurable, and to make measurable what is not so.  Since the WHO declaration in 
1948, HRQoL measurement has become a field of science on its own, generating a 
myriad of publications, and new questionnaires for measuring HRQoL are constantly 
being developed (82).   
Generally, HRQoL is measured with self-administered or interviewer-administered 
questionnaires consisting of a group of questions, called items, for the patient to 
answer. The response scoring system can differ between the simplest types, such as a 
visual-analogue scale, to a Likert scale, where the patient chooses between different 
response options for each question. Typically, there are between two to six response 
options, ranging from the worst possible to the best possible option (78).  
Questionnaires can be designed with the purpose of differentiating between patient 
groups at a point of time, i.e. discriminative questionnaires. Such questionnaires are 
typically apt for cross-sectional surveys. On the other hand there are evaluative
questionnaires, designed to evaluate longitudinal changes in HRQoL within patients, 
more apt for detecting improvement or deterioration in HRQoL for instant during a 
clinical trial. There is also a distinction between disease-specific and generic 
questionnaires. Generic questionnaires can be used for any group of patients, and are 
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particularly apt for comparing HRQoL between patient groups, i.e. measuring the 
relative burden of a disease. Disease-specific, or disease-sensitive, questionnaires 
have the opportunity of covering areas known to be affected by a given disease, and 
are thought to be more able to detect HRQoL changes over time within the specific 
populations (76). With this in mind, each type of HRQoL instrument has its strengths 
and weaknesses, and there are criteria all questionnaires should fulfil to demonstrate 
their measurement ability (83). 
The process of development and validation of measurement instruments, i.e. HRQoL-
questionnaires, should secure that the questionnaire measures what it is intended to 
measure, i.e, its validity is good, and that the HRQoL score produced is precise, 
reproducible and free from error; i.e. its reliability is good. In addition, particularly 
evaluative questionnaires should demonstrate the ability to detect real changes in 
HRQoL score over a period of time, even if these changes are small; this ability is 
called responsiveness.  
There are different ways to test for validity, reliability and responsiveness. Validity 
testing is the process of demonstrating that an instrument actually quantifies what it 
seeks to measure, and that it is useful for this purpose. In lay terms, this means to 
demonstrate that the items chosen are rational, cover all the aspects that we want to 
measure and that they are not redundant or biased. The questionnaire should also be 
easy to understand, not too long and available in the appropriate language for the 
patient. If a gold-standard instrument exists, validity can be tested by examining the 
correlation of scores between the gold standard and the new questionnaire; this is 
called concurrent validity. A more comprehensive way of testing validity is to 
examine the construct of the questionnaire, i.e. construct validity, which usually 
involves testing of correlation between the items. Traditionally this has been done by 
factor analysis, demonstrating that sub-groups of items in the questionnaire actually 
correlate to each other and that these groups of items actually represents the areas or 
domains intended to measure when constructing the questionnaire.  
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Reliability implies the degree to which an instrument is free from random error. The 
traditional reliability coefficient, Cronbach’s Į, indicates how well an individual item 
correlates with the other items in a questionnaire; this is also called internal 
consistency. A reliability coefficient above 0.85 is said to be necessary if the 
questionnaire is to be used at the individual level. Test-retest reliability or 
repeatability tests the correlation between scores from the same individual (or group) 
assessed on two separate occasions, given that their clinical condition is stable. If 
reliability is good, the variability of scores between patients (the signal) should be 
larger than the intra-individual variability (the noise). 
Demonstrating responsiveness is commonly done by examining statistically different 
changes in mean score for patient groups over time, for instance by demonstrating a 
significant improvement of HRQoL scores after an intervention. Responsiveness is 
compromised by floor effects (when persons with the worst score can deteriorate 
further without this being detected by the questionnaire) and ceiling effects (when 
persons with the highest score can improve further without this being detected).  
Questionnaires 
The Short Form-36 (SF-36) is a generic multidimensional HRQoL questionnaire, 
measuring eight general health concepts: Physical functioning, role limitations due to 
physical health problems (role-physical), bodily pain, general health perceptions, 
vitality, social functioning, role limitations due to emotional problems (role-
emotional), and mental health. The physical functioning, role-physical and bodily pain 
scales measures primarily physical health, whereas the mental health, social 
functioning and role-emotional scale primarily measure mental health. The vitality 
and general health scale are sensitive to both physical and mental health. The scale is 
extensively used in different medical fields, and has proved to be a valid and reliable 
tool for measuring HRQoL (84-86). The SF-36 has been used in previous studies of 
HRQoL in AD (87, 88).  
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The Psychological General Well-Being Index (PGWB) is a validated generic HRQoL 
questionnaire that has been translated into several languages, intended to measure the 
subjective feeling of psychological well-being (89-91). The 22 items group in six sub-
dimensions, each measuring six concepts: anxiety, depression, positive well-being, 
self-control, general health and vitality. Each item is scored from zero to five on a six-
point Likert scale, and the sum of all items is used to calculate a score for each 
dimension and a total score; a higher score indicates a higher HRQoL level.  
In other endocrine disorders, both the SF-36 and the PGWB have been used to 
validate disease-specific questionnaires, i.e., for growth hormone deficiency (92, 93), 
acromegaly (94) and Cushing syndrome (95). Until now, no AD-specific HRQoL 
questionnaire has been developed. However, a valid and reliable AD-specific 
questionnaire is needed to better detect changes in HRQoL over time, both in clinical 
trials, and during the follow-up of individual AD patients.  
Addison’s disease 
Definition 
In primary adrenal deficiency (PAI), i.e., Addison’s disease (AD), the adrenal cortex 
produces insufficient amounts of GCs, mineralocorticoids and adrenal androgens. 
Irrespective of cause, the lack of these hormones produces a characteristic clinical 
picture, first described by Thomas Addison in 1855. In his classic paper “On the 
constitutional and local effects of disease of the suprarenal capsule” he described 11 
cases of adrenal failure, combining patient history, clinical features and necropsy 
findings to a recognisable clinical syndrome excellently illustrated by hand-made 
illustrations (96). In this publication he gives the first clinical description of PAI: 
The leading and characteristic features of the morbid state to which I would direct 
attention, are, anaemia, general languor and debility, remarkable feebleness of the 
heart’s action, irritability of the stomach, and a peculiar change of colour of the skin, 
occurring in connexion with a diseased condition of the “supra-renal capsules”. 
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During his lifespan, Thomas Addison was not acknowledged for his work, and it was 
eventually Trousseau who accredited him for his work and named the syndrome 
Addison’s disease (97). 
Epidemiology 
AD is rare, with a prevalence of 110-140 per million and an incidence of 4.4 – 5.6 per 
million (98, 99). There is a female preponderance, and although AD can occur at any 
age, the peak age is around 40 years.
AD may appear isolated, however more than 50% of AD patients have other 
autoimmune diseases, that is, an autoimmune polyendocrine syndrome (APS) (100, 
101). APS1 is an autoimmune recessive disorder, caused by mutations in the 
autoimmune regulator gene (AIRE); more than 70 mutations have been identified 
(102). AIRE is involved in the thymus’ process of identifying and destructing 
immature autoreactive T lymphocytes; a defective AIRE gene results in loss of self-
tolerance by allowing autoreactive T-lymphocytes to enter the circulation (102). APS1 
patients are at risk of developing additional autoimmune diseases over time, but the 
three main manifestations are autoimmune hypoparathyroidism, AD and chronic 
mucocutaneous candidiasis (103). The prevalence of APS1 is around 1:80000 in most 
populations (104), except for higher prevalence in more homogeneous populations 
(105). 
APS2 comprises AD in combination with another organ-specific autoimmune disease, 
most commonly autoimmune thyroiditis (˜50%), but other autoimmune diseases such 
as primary gonadal insufficiency (˜7%), type 1 diabetes mellitus (˜10%), vitiligo, 
pernicious anaemia, alopecia, celiac disease and other are not unusual. The term 
APS2 is sometimes used for AD in combination with any organ-specific autoimmune 
disease (106). Of note, some authors includes only AD in combination with either 
hypothyroidism or type 1 diabetes mellitus in APS2, and uses the term APS3 for 
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thyroid autoimmunity in combination with another autoimmune disease and APS4 for 
two or more organ-specific autoimmune diseases to describe other combinations of 
autoimmune diseases (107), but these terms are not in common use. 
Pathogenesis 
AD can be caused by developmental defects, destruction of the adrenals by tumours, 
bleeding or infection, and impaired steroidogenesis. In Caucasians, the most common 
cause is autoimmune inflammation and destruction of the hormone-producing cells in 
the adrenal cortex (108). The autoimmune destruction of the adrenal cortex is 
believed to develop gradually over time, with overt symptoms first appearing when 
adrenal residual function is very low (106) (Figure 6).   
The high prevalence of concomitant autoimmune disease in AD is linked to a 
common genetic susceptibility for autoimmune diseases. A combination of multiple 
genes acting together with an environmental trigger is believed to elicit the 
autoimmune destruction of the adrenal cortex, although the precise pathogenesis is 
still uncertain (106). To date, environmental triggers have not yet been demonstrated.  
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In 1992, the enzyme steroid 21-hydroxylase (21OH) was identified as the antigen for 
the auto-antibodies involved in AD (109), but later it was demonstrated that the auto-
antibodies do not inhibit the enzyme activity in vivo (110). 21OH antibodies 
(21OHAb) are now seen as a bystander for the ongoing autoimmune process, more 
than a causative factor, present in more than 95% of recently diagnosed AD patients 
(100). The frequency of positive 21OHAb in the general population is around 0.5%, 
but higher in patients with other autoimmune diseases and in first degree relatives to 
AD patients (111). Studies have shown that the predictive value of 21OHAb for 
future clinical autoimmune AD is 30-40% at 10 years (107, 111, 112). Determinants 
of the future risk for clinical AD are the response to ACTH stimulation test, 21OHAb 
titre, male gender and the number of associated autoimmune diseases (111).  
Although T-lymphocytes reactive to adrenal cortex cells were discovered already in 
the 1960s (113), the exact mechanism for T-cell mediated adrenal destruction in AD 
is still not clear. In APS2 a breach of peripheral tolerance due to defective 
CD4+CD25+ regulator T-cells and reduced expression of caspase-3 have been 
demonstrated (114, 115).   
Symptoms and Diagnosis 
The difficulty of diagnosing AD lies in considering the possibility, as symptoms may 
be nonspecific and subtle in the early stages and progress insidious. A German survey 
found that less than 50 percent of women and less than 30 percent of men were 
diagnosed within six months with symptoms, and more than 67 percent of patients 
had consulted three doctors or more before they were diagnosed (116). The most 
common presenting symptoms are fatigue, loss of appetite with nausea and other 
gastrointestinal symptoms, salt craving and muscle and joint pain. Usually there are 
accompanying signs of pigmentation, weight loss and orthostatic hypotension (98). 
Once the suspicion of AD arises, measurement of basal cortisol and ACTH is often 
sufficient to establish the diagnosis. A morning cortisol below or in the lower 
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reference range in combination with an ACTH level above reference range confirms 
the diagnosis (117). Aldosterone is typically below, plasma renin activity (PRA) 
above, and DHEAS below their reference ranges. 
When basal tests are equivocal, testing with cosyntropin (synthetic ACTH) can be 
indicated. Administration of Synacthen 250ȝg i.v. or s.c. should elevate cortisol above 
500 nmol/L after 30 or 60 minutes (108). It has been argued that the conventional 
Synacthen dose is supra-physiological, risking to overlook early adrenal insufficiency, 
and that a low dose Synacthen at 1 ȝg i.v. or s.c would be more appropriate (118). 
However, others have pointed out that in PAI, as opposed to in secondary adrenal 
insufficiency (SAI), basal ACTH levels are already maximally elevated, and that the 
low dose test will not provide a higher diagnostic sensitivity (119). 
Once primary adrenal insufficiency has been confirmed, aetiology should be 
determined. As the most common cause in adults is autoimmune adrenalitis, testing 
for 21OHAb is the test of first choice (120), reported to be present in 96 percent of 
the patients (98, 99). If positive, the patient should also be screened for concomitant 
autoimmune disease, particularly autoimmune thyroid disease and diabetes mellitus 
(APS2). In patients suspected to have mucocutaneous candidiasis or 
hypoparathyroidism, testing for APS1 with anti-Interferon-Ȧ antibody is warranted 
(121). 
In the rare case that 21OHAb is negative; a CT of the adrenals can identify any causal 
adrenal bleedings, tumours or infection (tuberculosis, HIV, fungal infections). In male 
patients with no other apparent cause, especially if concomitant neurological 
symptoms, testing for very long chain fatty acids (VLCFA) can identify patients with 
adrenoleukodystrophy (122). Testing for 17-hydroxy progesterone (17OHP) can 
identify patients with congenital adrenal hyperplasia (CAH); however these patients 
are generally diagnosed in childhood.  
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Replacement therapy 
AD is a chronic disease, and patients depend on appropriate lifelong replacement 
therapy with GCs in combination with a mineralocorticoid. The lack of GCs, or 
cortisol, mandates appropriate replacement therapy. This subject will be covered 
comprehensively below.
The lack of aldosterone will lead to increased loss of sodium in the urine and 
increased potassium levels, which in turn will lower the blood pressure and induce 
hypovolemia. Untreated, this can lead to overt hypovolemic shock, or adrenal crisis. 
Aldosterone is difficult to synthesize; therefore, the synthetic mineralocorticoid 
Fludrocortisone is used for replacement. Once daily doses of 0.05-0.2 mg are 
recommended (108). One study found that 0.2 mg was the most appropriate dose, and 
concluded that the most common doses of 0.05-0.1 mg fludrocortisone might be too 
small for many AD patients (123).  It is possible that a fludrocortisone dose increase 
could facilitate reduction of GC dose when needed, although the evidence for this is 
scarce. On the other hand, overdosage may lead to hypertension, peripheral oedema 
and possibly increase the risk of cardiovascular disease (CVD). Nevertheless, a dose 
increase and/or increased salt intake are warranted for patients during hot climate and 
during strong perspiration (124). Fludrocortisone do not replicate the physiological 
dip in aldosterone during the night; this has unknown significance (125). Higher 
fludrocortisone doses may be needed in patients treated with synthetic GCs, as these 
have a lower mineralocorticoid effect than hydrocortisone and cortisone. 
There is an absolute lack of adrenal androgens in both AD men and women, but the 
decrease in total androgens is much larger in women. This is particularly true for 
women with ovarian failure (both premature failure and normal menopause).                  
There is still no consensus on the need for DHEA replacement therapy in AD. The 
first clinical trial reported improved well-being and improvement in mood and sexual 
function for women with primary or secondary adrenal failure with DHEA 50 mg 
when compared to placebo (126). Subsequent studies have reported partly conflicting 
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results and partly minor effects on HRQoL, possible beneficial effects on bone and no 
effect on sexual function (5, 127-129). However, most clinicians will consider 
prescribing androgens to individual AD females who are still symptomatic despite 
appropriate dosage of GCs and mineralocorticoids. It is generally recommended to 
start with low doses such as 25 mg once a day, doses can then be increased to 50 mg 
depending on clinical effect, the occurrence of side-effects (acne, sweating, hirsutism) 
and resulting androgen levels (testosterone, androstenedione, DHEAS) (130). If no 
positive subjective effects are noted within 6 months, discontinuation of DHEA 
treatment is recommended (5, 60). Transdermal patches supplying testosterone 150 
ȝg/day have been tested only in women with SAI; only minor effects were noted on 
HRQoL, but bone density, mood and sexual function improved (131).  
Acute adrenal crisis 
Acute adrenal failure, or Addisonian crisis (AC), is a life-threatening complication of 
chronic AD, and can also be the presenting symptom leading to the diagnosis of AD. 
An untreated absolute or relative lack of cortisol and aldosterone will lead to 
hypotension and/or hypovolemic shock, often accompanied with abdominal pain, 
vomiting and fever (108). 
Hahner et al. documented a frequency of AC at 6.6 events per 100 patient years, the 
main precipitating events being infectious disease (57%), major surgery (7.2%) and 
physical stress (7.7%). The risk was increased for patients with additional 
comorbidities (132). In a postal survey, White et al. found that 47% of the patients 
reported that they had been in need of hospital treatment since the time of diagnosis, 
10 percent on more than four occasions (133). 
In a retrospective study in AD, Erichsen and co-workers found that AD was given as 
the principal death diagnosis in 15%, and infectious disease in 10% of patients. In 
addition, sudden death accounted for 9.2% of the deaths, compared with 5.3% in the 
general population. It is likely that AC contributed to deaths in all the three diagnose 
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groups (134), as AC is often precipitated by infectious diseases and can result in 
sudden death if appropriate treatment is not provided. 
In healthy subjects, endogenous production of cortisol is increased during stress, and 
patients with AD need to increase their GC doses accordingly to cover the increased 
demand in case of events such as infections, strenuous activity, major surgery and 
labour. Especially in conditions leading to compromised absorption of cortisol and 
fludrocortisone such as gastroenteritis, patients are at risk of rapidly developing AC 
unless appropriately treated with intravenous fluids and cortisol. Hence, both patients 
and health care professionals need to be properly educated about the required action 
in the event of AC symptoms.  
Mortality 
Despite conventional replacement therapy, the standard mortality rates (SMR) have 
been found to be more than doubled in AD, with higher mortality rates for patients 
with APS1 when compared to APS2 (135). The major causes of death are 
cardiovascular disease, malignancy and infectious diseases (136). Another study did 
not find an increased overall SMR, but mortality was increased in patients diagnosed 
before the age of 40, especially in males, and acute adrenal failure was found to be a 
major cause of death (134). This study did not find any increase in CVD in AD.  
Risk of cardiovascular disease 
Exogenous or endogen hypercortisolism is known to increase the risk of 
cardiovascular disease, and several studies have demonstrated a strong relationship 
between GC dose and CVD risk factors in adrenal insufficiency. In SAI, reduction of 
GC doses resulted in reduction of cholesterol, triglycerides and weight (137). 
Filipsson and co-workers demonstrated that the metabolic CVD risk profile in SAI is 
related to the daily dose of GC. Hydrocortisone equivalent doses of less than 20 mg/d 
did not adversely affect metabolic risk factors. Furthermore, patients treated with 
hydrocortisone and prednisolone had higher HbA1c and waist-hip-ratio respectively, 
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than patients treated with cortisone acetate (138). This is interesting, knowing that the 
replacement therapy in the mortality study showing increased risk of CVD in AD 
were predominately OHC (136), while in the study showing no CVD risk patients 
were mainly treated with cortisone acetate (134). 
In AD, a higher prevalence of central adiposity, impaired glucose tolerance and 
dyslipidemia, all well-known independent risk factors for cardiovascular disease, has 
been demonstrated (139). The same study showed that patients with AD use more 
antihypertensive drugs and lipid-lowering agents than the background population, 
indicating an unfavourable metabolic state and possibly increased cardiovascular 
morbidity. Another study found increased prescription of lipid-lowering drugs and 
antihypertensive agents in AD when compared to the general population (140). 
Explanations might be supra-physiological GC replacement doses, and altered diurnal 
profile (141).  
Carbohydrate metabolism 
While too high GC doses can impair glucose tolerance in AD, the very low nighttime 
cortisol levels seen with conventional OHC may reduce late night glucose levels.  
Patients with SAI on OHC treatment have reduced glucose levels during the night, 
which could possibly impair sleep quality and reduce daytime energy (142). A recent 
study demonstrated that also AD patients without concomitant type 1 diabetes can be 
susceptible to low night time glucose levels (143). In AD patients with concomitant 
diabetes mellitus inherent variation in cortisol levels on OHC can also cause 
fluctuations in glucose levels that can be difficult to handle; as cortisol troughs will 
increase insulin sensitivity and cortisol peaks will decrease it (144, 145). In addition 
to the lack of cortisol, AD patients have a decreased adrenal adrenaline output, further 
impairing counter-regulatory responses to hypoglycaemia (1, 146). The incidence of 
sudden death is increased in AD patients when compared with the normal population 
(134), for which hypoglycemia could hypothetically be a contributing factor.  
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Patients with AD on conventional OHC therapy complain about fatigue, dizziness and 
concentration difficulties (147, 148), especially in the early morning. In one study 
high-calorie glucose-rich food alleviated these symptoms (149), but another showed 
no effect of glucose infusion on neurocognitive function (150). Whether these 
morning symptoms could relate to low glucose levels and neuroglycopenia is not 
clear.  
During parts of the day, especially in the afternoon, AD patients have higher cortisol 
levels than normal (151, 152). Increased evening exposure to cortisol reduced glucose 
tolerance, insulin secretion and insulin sensitivity in healthy young adults (30). Hence, 
mimicking the circadian cortisol rhythm might be of importance both during the night 
and day, and a recent study found that reduced cortisol exposure during the afternoon 
reduced weight, blood pressure and HbA1c in AD patients (153).  
Bone metabolism 
GCs inhibit osteoblasts, stimulate osteoclasts and inhibit intestinal absorption of 
calcium, hereby reducing bone mineral density (BMD). Too high doses of GCs in AD 
can therefore lead to reduced BMD in AD, and studies have demonstrated an inverse 
correlation between GC dose and BMD (154-156) or bone formation markers (157). 
Type of GC also seems to matter, as synthetic long acting GCs seem to have a worse 
impact on bone than OHC (158, 159). Studies on BMD in AD have been inconsistent, 
but the largest study including 293 AD patients found lower BMD in patients than in 
controls (155). On the other hand, a recent study which included patients on lower GC 
doses, demonstrated BMD within reference range in patients with AD or CAH when 
compared to controls (159). A register-based study identified hip fractures in 6.9% of 
AD patients versus in 2.7% of controls (160). Surprisingly, the risk of fracture was 
highest around time of AD diagnosis (one year before and one year after), suggesting 
that both too low and too high GC levels could affect bone.  
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AD patients also lack adrenal androgens, which may contribute to loss of bone mass 
in females. In a randomized double-blind trial, Gurnell et al. found that six months 
treatment with DHEA reversed bone loss at the femoral neck, but not at other sites, in 
female AD patients (128). In addition, the prevalence of premature menopause is 7% 
in AD (98), which also could influence bone health in this patient group. Given the 
slightly conflicting results, BMD measurements are not always recommended for 
regular follow-up in AD (108), but might be indicated in patients with premature 
ovarian failure and in patients on high doses of GCs, especially when synthetic GCs 
are used.  
Infections 
AD patients lack the physiological increase in cortisol levels normally produced under 
stressful conditions, and during infections they depend on extra doses of GC. 
Mortality studies found that infections are a more common cause of death in AD than 
in reference populations (134, 136). A recent study showed high rate of prescription 
of systemic antibiotics in AD, both before and after the time of diagnosis (140). A 
new cohort study applying pharmaceutical records found that the incidence of 
infections was one and a half times higher in AD than in controls, with higher risk for 
fungal and viral infections than for bacterial infections (161).  Here, the overall 
incidence of hospital admissions due to serious infections was five times higher, the 
incidence of pneumonia 10 times higher and of urinary infection four times higher in 
AD than in controls.  
Even though studies on defects in immunity in AD are lacking, the increased risk of 
infection could be a result of the autoimmune disease per se, as defects in the cellular 
innate immunity have been found for other autoimmune diseases such as type 1 
diabetes (162). One could speculate that the high ACTH levels in AD patients could 
convey anti-inflammatory effect through the melanocortin receptors, although 
evidence is lacking. However, given the important role of GCs in inflammation, 
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suboptimal GC replacement therapy could theoretically contribute to an increased risk 
of infection in AD.  
Quality of life in AD 
Patients with AD reproducibly report of reduced HRQoL when compared with 
healthy reference populations. Løvås and co-workers reported HRQoL scores in 79 
Norwegian AD patients; lower scores were found in the domains vitality and general 
health for the SF-36 questionnaire, and for the Fatigue questionnaire (87). Lower 
scores for physical function were found only among women, and lower scores for 
mental health only in men. No significant differences in scores were found between 
patients with isolated AD and patients with APS. Working ability was lower in AD 
than in the reference population. These findings were confirmed in a nation-wide 
study from Norway involving 426 AD patients (98). Here, the vitality, general health, 
social functioning and role physical scores were low in AD. Thirty percent of the 
working age patients received full or part time disability benefit compared with 11% 
in the reference population, indicating that AD has a serious impact on the daily lives 
of the patients. In a cross-sectional study including 256 German patients, Hahner and 
co-authors found significantly reduced HRQoL levels in patients on conventional 
replacement therapy, irrespective of age, sex, concomitant disease and primary or 
secondary adrenal failure. The largest impairment was seen in the general health, 
physical function and vitality scores with the SF-36, and for exhaustion tendency and 
anxiety with the two other generic questionnaires applied. When comparing the 
results for the SF-36 general health and vitality scores from different AD studies in 
different countries, there is a remarkable consistency of score levels (87, 88, 98, 128), 
indicating that affection of these domains are indeed characteristic for AD. Both 
German and Norwegian studies showed that the SF-36 general health scores for AD 
patients were similar to the published scores for patients with type 1 diabetes (163) 
and patients with diabetic foot ulcers (164), but higher than in patients with 
rheumatoid arthritis (165).  
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In contrast to the normal mental health scores mentioned in studies applying the SF-
36 questionnaire (87, 128), studies applying alternative questionnaires have shown 
psychological and mood impairments in AD (126, 128, 166). Also, a Danish registry 
study investigated the risk of affective disorders in AD by identifying AD patients 
among patients admitted for affective disorders. Compared to patients with 
osteoarthritis, AD patients had a significant two times greater rate of affective 
disorders, but the rate of depression was not significantly increased, and the overall 
incidence of affective disorders in AD was low (167). The highest rate was found the 
first year after diagnosis.   
The reason for the reduced HRQoL in AD is not clear cut. Currently, unphysiological 
or insufficient GC replacement is believed to be the major explanation for the reduced 
HRQoL in AD (60, 88). Some authors have suggested that the lack of DHEA could 
be a causative factor (126), although the largest placebo-controlled randomized study 
detected only minor HRQoL benefits of DHEA in AD (128). Another theory is that 
the autoimmune state in itself will compromise HRQoL, given that HRQoL are 
affected in several autoimmune conditions (163, 165, 168). A recent study in patients 
on thyroid replacement therapy compared SF-36 scores between patient with 
autoimmune hypothyroidism and postoperative hypothyroidism, demonstrating lower 
scores in patients with anti-thyroid peroxidase antibodies (169), which supports this 
theory.  
A survey showed that although achieving HRQoL improvement was seen as both a 
major goal and a major challenge in AD, HRQoL measurement in AD patients is not 
routinely assessed by clinicians (60). This could be because no AD-specific HRQoL 
questionnaire has been available, or of the difficulty of interpreting HRQoL scores in 
individual patients. An AD-specific questionnaire containing questions related to AD 
symptoms could be of assistance in identifying patients with poor functioning, who 
are in need of a more individualized treatment strategy.  
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Sleep 
In AD patients on conventional replacement therapy, nocturnal levels of cortisol are 
unphysiologically low, especially during the last part of the night. In the same period, 
ACTH levels, and probably CRH levels, are higher than normal. How this affects 
sleep in AD is not clear, as results from previous studies are not entirely consistent 
(72, 170, 171). Because of the close links between the sleep cycle and the circadian 
activity of the HPA axis, restoring the physiological circadian cortisol rhythm in AD 
patients could possibly affect sleep. 
Glucocorticoid treatment in AD 
A historical perspective 
When Thomas Addison in his classical publication “On the constitutional and Local 
Effects of Diseases of the Supra-Renal capsules” in 1855 first described the typical 
symptoms and findings of adrenal failure, no treatment was available and the disease 
was always lethal (96). At the end of the 18th century there was a growing interest for 
the function of what were then called “the ductless glands” (thyroid, adrenals, thymus, 
pituitary), although there were conflicting views of their function. Some believed that 
the glands had an excretory function and hence that removal of the gland would lead 
to accumulation of toxins causing disease; others believed that their function was 
primarily to secrete substances to the blood. The adrenals were believed to produce a 
medullary derived substance to the blood, essential for the muscular function 
especially in the heart and the great arteries (172). This secretory theory was based on 
the physiological effects demonstrated from experimental injections of adrenal 
extracts, and in 1896 William Osler published a report of six cases of Addison’s 
disease of whom one patient radically improved after the use of adrenal extracts 
(173), describing the method for preparing the extract as well as the clinical result:
On May 16 the treatment with suprarenal extracts begun. Thirty-six pigs’ suprarenals 
were obtained at the time of slaughtering, cut up finely, thoroughly powdered with 
pestle and mortar, and to this mass about six ounces of pure glycerine were added, 
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and the whole allowed to macerate for thirty-six hours in a refrigerator. The mixture 
was then filtered several times through fine-meshed gauze. The filtrate consisted of a 
reddish-brown syrupy fluid of a rather disagreeable odor. After filtering there were 
thirty-eight drachms of the extract, so that one drachm corresponded to a capsule. 
The patient began with half a drachm three times a day. 
...He left the hospital on September 10. The change in his condition had been very 
remarkable. When admitted he could scarcely walk to the bed, and was profoundly 
asthenic and emaciated. The general appearance had improved wonderfully; he was 
bright and active, and said he felt vigorous. His weight on discharge was one hundred 
and eighteen pounds, a gain of nineteen pounds. The pigmentation was unaltered. 
Although this early report seemed very promising, the treatment results were not 
always that positive. A year later, in 1897, Francis Kinnicutt published the results of 
48 AD cases treated with some form of adrenal extract, describing that six patients 
were cured, two improved, 18 unimproved and in two patients the symptoms were 
aggravated. This is maybe as expected as the content of cortisol required to ameliorate 
symptoms probably was highly variable and the mineralocorticoid effect small, and 
that a high content of adrenaline (slaughtered pigs) could give detrimental side-
effects.   
In 1925, Dr. Rowntree of Minnesota presented encouraging results obtained from “the 
Muirhead treatment” at the Annual Meeting of the Association of American 
Physicians (90). This consisted of adrenaline given hypodermically or rectally three 
times a day, and the whole adrenal gland given by mouth three times a day. The 
treatment was named after the first patient, Dr. A. L. Muirhead, a professor in 
pharmacology, who presented at the Mayo clinic in 1920, suffering from advanced 
AD. He improved to describe his experience in the Journal of American Medical 
Association under the title “An Autograph History of a Case of Addison’s disease” in 
1924, but unfortunately he died 16 months later. Of the 12 patients on the Muirhead 
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regimen reported in the 1925 publication, five died without apparent benefits of the 
treatment, and seven were reported still alive.  
In the late 1920’s two groups of physiologists, Hartman and associates at the 
University of Buffalo and Swingle and Pfiffner at Princeton University, had 
developed adrenal extracts that prolonged survival in adrenalectomised animals and 
controlled symptoms in AD (174). They manufactured the extract on a large scale, 
which Dr Rowntree at the Mayo Clinic used in treatment trials of AD patients in 1931 
(175). The extract preparation was an expensive and time-consuming process; 1000 
kg of beef adrenals yielded about 1 kg of dry residue to be refined further to 25 g 
adrenal extract (176). Hence, the hunt for the active component called “cortin” from 
adrenal cortical extracts begun.  
At the Mayo Clinic in Rochester US, Edward C. Kendall and associates succeeded in 
preparing what they first believed was a pure cortin extract in 1934. In Basel, 
Thaddeus Reichstein found 29 structurally similar steroids, of which six possessed 
“cortin-activity”. Half of these were identified by Reichstein, and half by Kendall, 
who also identified an additional substance. Probably the most important substance 
named “Compound E” was later identified as cortisone at four different laboratories, 
including Reichstein’s and Kendall’s. For their achievements they, together with 
Philip Hench who discovered the effectiveness of cortisone in treating rheumatoid 
arthritis, were awarded the Nobel Prize in Medicine and Physiology already in 1950 
(44, 176, 177). 
The first semisynthetic steroid available for treatment in AD was 
desoxycorticosterone acetate (DOCA) synthesised by Reichstein from deoxycholic 
acid in 1937 (178, 179), administered once daily i.m. or s.c. DOCA was later shown 
to lack glucocorticoid and anti-inflammatory effects, and AD patients were therefore 
instructed to remain on a diet rich in carbohydrates to avoid hypoglycaemia. Although 
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mortality was reduced by DOCA, patients were still at risk for AD crisis during stress 
(180). 
After cortisone became available in 1948, Reichsteins “Compound F” was in 1951 
identified as hydrocortisone, and it became clear that hydrocortisone was the 
substance produced by the normal adrenal cortex (178, 181). The following decade it 
was discovered that modification of anti-inflammatory and mineralocorticoid effects 
could be achieved by alterations in the steroid skeleton, producing prednisone, 
prednisolone and fluorocortisone in 1954, triamcinolone in 1956, methyl-
prednisolone in 1957 and dexamethasone in 1958. 
Although low blood pressure, a reduced sodium concentration and a high potassium 
level were recognised features of AD, it was Robert F. Loeb that in 1932 
demonstrated that excessive urinary salt loss was responsible (174). He examined the 
blood of three patients with AD, discovering a striking decrease in the sodium content 
in their blood. Further studies in adrenalectomised dogs and cats confirmed this 
finding (182), and later gave evidence for prolonged survival with sodium 
supplements. Although it was noted that adrenal extracts had remarkably low 
mineralocorticoid activity, evidence for adrenal aldosterone production was presented 
as late as 1948 (183, 184). After DOCA and oral cortisone became commercially 
available, combination treatment was common, as DOCA possessed 
mineralocorticoid effect. In 1955, 9-Į-fluorocortisone was discovered to have a 
superior mineralocorticoid effect and favourable pharmacokinetics, and replacement 
with oral cortisone or hydrocortisone in combination with fludrocortisone became 
possible (185, 186) (Figure 7). 
Present conventional glucocorticoid replacement therapy 
Available oral replacement therapy ensured that AD was no longer a fatal disease, and 
made patients live near normal lives. In 1963 Sir Derrick Dunlop published a report  
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of 86 AD patients he had cared for between 1928 and 1958, showing that while all 
patients died during the first 10 years, after cortisone became available only one of his 
patients had died (180). That paper also stated that conventional AD replacement by 
then was cortisone 25-37.5 mg/d in combination with fludrocortisone 0.1-0.2 mg/d.  
Over the following 50 years the GC replacement in AD has been virtually unchanged. 
Being the normal GC produced by the adrenal, OHC is the most common treatment 
choice worldwide (187). Cortisone acetate (CA) is considered equally effective as 
OHC and is preferred in some countries, where OHC is not easily commercially 
available. CA needs to be converted to hydrocortisone by liver 11ȕ-HSD to have 
biological effect.  In some countries long-acting GCs such as prednisolone and 
dexamethasone are also used (188, 189), despite the resulting unphysiological 
pharmacodynamic effect (108). There are also concerns that the synthetic long-acting 
GCs results in continuous stimulation of the GR, probably increasing the risk of 
detrimental side-effects (24, 60, 190).  
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In the recent decade there has been a number of reports showing that patient on 
conventional replacement therapy have reduced HRQoL (87, 98, 128), increased risk 
of osteoporosis (155, 159, 160), increased mortality rate (134-136) and possibly 
increased risk of cardiovascular disease (191, 192). Newer estimates of the endogen 
cortisol production rate at only 5.4–6.1 mg/m2/day have caused concern that AD 
patients are receiving too high doses (193, 194), and slightly lower daily doses than 
before of hydrocortisone 15-25 mg/d or cortisone acetate 20-30 mg/d are now 
recommended, allowing for less than 100% bioavailability and first-pass liver 
metabolism. These concerns have sparked interest in improving the therapeutic 
regimes.  
Efforts have been made to optimise treatment regimens by various strategies. A cross-
sectional study examined cortisol day curves in 32 AD patients (PAI and SAI), 
showing that 75% of patients required a dose reduction and 56% a change of drug or 
drug regimen to achieve acceptable cortisol levels during the day (157). The only 
randomised placebo-controlled trial available demonstrated that twice daily dosing 
was better than once daily (195). Howlett and Groves lead studies that examined 
cortisol day curves and suggested that thrice daily OHC normalised cortisol levels 
better than twice daily dosing (152, 196). Mah and colleagues demonstrated large 
inter-individual differences in pharmacokinetics after intake of 10 mg hydrocortisone 
in patients with adrenal insufficiency. By individually adjusting doses of thrice daily 
OHC according to weight or body-surface-area (BSA), the variability in peak cortisol 
and cortisol area under the curve (AUC) were significantly reduced (151). In a cross-
sectional analysis, Bleicken and co-workers examined impact of number of OHC 
doses on HRQoL; only minor differences were found between twice and thrice daily 
dosage, favouring two daily doses (197). However, patients on doses more than 30 
mg/d scored significantly worse than patients on lower daily doses.  The same authors 
also found that type of GC replacement (OHC, CA, Prednisolone) did not impact 
HRQoL scores in this patient group (188). A recent double-blind study compared two 
with four doses, with the same daily dose. They found that four doses increased the 
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serum cortisol AUC, but could not detect any significant difference in HRQoL scores 
(198). Current recommendations state that OHC should be given in two or three daily 
doses, with one-half to two-thirds of the daily dose in the morning, and the 
subsequent dose approximately five hours later (60, 130, 190). 
The available conventional OHC or CA cannot reproduce the physiological circadian 
cortisol variation (199). The ideal GC replacement therapy would mimic the 
endogenous cortisol rhythm, with a nadir at bedtime, gradually rising levels until the 
early morning peak before waking, followed by decreasing levels during the day 
(200). Instead, with OHC, cortisol levels are very low during the night and early 
morning, which may contribute to low nighttime glucose levels and symptoms like 
fatigue, mild nausea or headache experienced by AD patients especially in the 
morning (143, 147). During daytime the cortisol level fluctuates, with supra-
physiological post-dose peaks followed by troughs before the next dose (151). This 
non-physiological cortisol profile is currently believed to be the major explanation for 
poor outcome in AD, but clinical trials confirming this hypothesis are lacking (60, 
88).   
Physical activity 
The adrenocortical and the adrenomedullary stress responses are closely linked. Both 
responses are compromised in AD (201-203), and strenuous exercise can trigger an 
adrenal crisis (132). Some authors advice patients to use an additional dose of 
hydrocortisone 5-10 mg during strenuous or long-lasting exercise and long-lasting 
psychological stress (124, 204). However, exercise studies in CAH patients have 
demonstrated a normal exercise capacity when compared with controls, despite lower 
cortisol and adrenaline levels. An extra stress dose of hydrocortisone was not found 
beneficial (146, 205, 206). Likewise, DHEA replacement produced no benefit on 
physical capacity in AD patients (207). More research is needed to clarify why AD 
patients experience fatigue in relation to physical activity, and how this should be 
prevented and treated.  
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Prevention and treatment of adrenal crisis 
Patients should be able to recognise stressful events that possibly result in AC, and be 
instructed to adjust their oral dose accordingly, to prevent progression to AC (124). 
They should be provided with a steroid card, stating their diagnosis and recommended 
treatment in the event of AC symptoms (208). Also, patients should be equipped with 
hydrocortisone for intramuscular or subcutaneous use in emergency to avoid delay of 
treatment (209). As a thumb rule, we advise patients to double or triple their daily oral 
GC doses during intercurrent disease, i.e., depending on the degree of body 
temperature. When modified-release hydrocortisone is used as replacement therapy, 
the additional dose should be given 6-8 h after the normal dose, due to the 
pharmacokinetic properties of the drug (60).  
Patients presenting with severe AC symptoms, vomiting or diarrhoea need to be 
admitted for treatment with intravenous hydrocortisone in combination with saline 
infusion. An immediate dose of 100 mg hydrocortisone is recommended, followed by 
infusion of 100-200 mg over the next 24 hours (108).   
In normal subjects, ACTH and cortisol increase significantly at start of surgery, but 
the largest increase is seen during reversal of anaesthesia. Earlier treatment 
recommendations were 100 mg hydrocortisone every 8 hour, starting at the induction 
of anaesthesia (210). These doses are supra-physiological (130, 211, 212) and 
hydrocortisone doses of i.v.100-150 mg/d are now recommended to prevent AC in the 
setting of major surgery, or during critical illness (108, 213).   
Pregnancy 
There is a physiological increase in serum cortisol levels during pregnancy due to the 
increase in CBG. The free cortisol level also increases during the last trimester. In the 
last trimester progesterone levels also increase, exerting an anti-mineralocorticoid 
effect. The foetus is relatively protected from maternal hypercortisolism due to 
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placental 11ȕ-HSD2 production. It is recommended to use the most physiological 
replacement therapy possible, to minimize the risk for mother and foetus. There is no 
consensus of routinely increasing the GC doses in all patients, as some authors state 
that doses rarely need to be increased (214), while others encourage a dose increase of 
50% in the last trimester to mimic the physiological increase in free cortisol (108). 
Mineralocorticoid replacement should be adjusted to blood pressure and potassium 
levels during pregnancy, as PRA is physiologically increased. Due to the anti-
mineralcorticoid effect of progesterone, an increase of the Fludrocortisone dose may 
be necessary during late pregnancy (204). During labour, some authors recommend to 
double the oral dose, or give hydrocortisone 50-100 mg i.v. (108, 204). During 
Caesarean section, i.v. hydrocortisone should be given as with major surgery. The 
doses can be tapered to normal within two days if no complications occur. During 
breastfeeding, OHC can be continued as usual, as less than 0.5% of the absorbed dose 
will appear in breast milk (215).  
Recent developments 
Lately, two new modified-release hydrocortisone formulations have been developed, 
both aiming for a more physiological circadian pattern of cortisol. Recent studies 
demonstrated that 24 h exposure of cortisol was reduced by dual-release 
hydrocortisone, resulting in reduction of body weight, blood pressure and HbA1c 
(153, 216). Also improvement in HRQoL was noted. Although such treatment 
successfully restored daytime cortisol levels to normal with once daily dosage, the 
normal late night increase in cortisol is not re-established. Restoration of this 
nighttime cortisol surge was however obtained by another modified-release 
hydrocortisone preparation (200, 217, 218). This preparation was later shown to have 
reduced bioavailability and too early drug release, leading to further modifications. A 
recent study with healthy dexamethasone-suppressed volunteers showed that twice 
daily dosing of DIURF-006 (10 mg morning and 30 mg evening) resulted in near 
normal daily cortisol AUC and peak cortisol; maximal absorption was also delayed, 
mimicking the physiological morning peak (219). Potential effects on well-being will 
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have to be investigated in future studies. Also, modified-release prednisolone was 
tested in AD patients in an open label pilot trial (220). One daily dose at bedtime 
improved HRQoL and reduced fatigue when compared to one daily dose of 
prednisolone in the morning.  
Merza and co-workers showed that mimicking the physiological circadian cortisol 
rhythm in AD is possible by intravenous infusion of hydrocortisone; in fact, ACTH 
levels were reduced towards normal levels already after 24 h treatment (221). Løvås 
and Husebye found that continuous subcutaneous hydrocortisone infusion (CSHI) 
enabled a fine-tuned control of GC delivery that allowed restoration of the circadian 
biorhythm in a few AD patients (222), suggesting that CSHI is a versatile method for 
further refinement of the GC replacement therapy. This method of GC delivery also 
provides us with a means to explore whether restoring the circadian cortisol rhythm 
can improve replacement therapy in AD. 
Monitoring glucocorticoid replacement 
Although the recent decades have produced increasing knowledge both in the field of 
AD and of replacement therapy, there is still no universal agreement about how to 
appropriately monitor GC replacement therapy. Some endocrinologists rely primarily 
or exclusively on clinical parameters and judgement to evaluate GC doses. One study 
proposed a clinical scoring system to identify over- and under-replacement (223), but 
although the scoring system correlated with serum cortisol measurements, there was 
no difference in score between the perceived overdosed and underdosed patients. 
There has also been concern that subtle over- and under-replacement might produce 
detrimental effects without obvious clues from the patient history and clinical 
examination. Monitoring HRQoL could be another possible method of detecting 
suboptimal replacement therapy, but until now an appropriate disease-specific 
questionnaire has been lacking. 
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Several laboratory tests have been proposed either as the main parameter for 
appropriate dosage, or as a supplement to clinical judgement. However, the major 
objection to this strategy is that levels of hormones in plasma or other samples do not 
necessarily reflect cortisol action on tissue or cellular level, and a relevant biomarker 
for optimal GC effect is lacking (224). 
Given the pulsatile nature of ACTH secretion and the short half time of ACTH in 
plasma, ACTH levels will be strongly influenced of the cortisol exposure the last 
hours before measurement. Due to the low nighttime cortisol levels on conventional 
oral treatment, ACTH will remain elevated in the morning and early daytime in most 
patients, despite adequate doses of GCs. Daytime ACTH levels will also be 
influenced by the timing of the measurement in relation to the dosage time, and can be 
difficult to interpret. Some papers have advocated that normalisation of ACTH levels 
imply over dosage, whereas others suggest that measuring ACTH has some clinical 
benefit (225). However, random ACTH measurement is of little value in monitoring 
conventional GC replacement (108, 226). 
Serum total cortisol has been the easiest and most available analysis for many years, 
although the measurement has obvious disadvantages. Interpretation requires 
knowledge about timing of doses and type of GC used, and preferably standardised 
absorption conditions. Random serum cortisol measurements have little clinical 
utility. Some have suggested measuring serum cortisol day curves despite that this is 
cumbersome to perform in all patients (152). Nevertheless, day curves could be useful 
in special situations, such as evaluating absorption issues or drug interactions. Mah 
and coworkers showed that serum cortisol four hours after the OHC morning dose 
explained 78% of the variability in cortisol AUC; therefore they suggested using 
weight-adjusted doses thrice daily, and produced a nomogram for optimisation of 
individual doses (151). This approach is easier and more effective than day curves, 
but use of the nomogram is limited to patients on thrice daily OHC. Also, this study 
was criticised for proposing too low doses for AD patients, because the study also 
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included patients with SAI, who might have residual adrenal cortisol production. A 
major limitation of serum total cortisol is that the correlation with the free and 
biologically active cortisol proportion depend on the CBG levels (227). This is 
particularly important under acute stress such as critical illness, because binding 
proteins will be down regulated resulting in a higher biologically active cortisol level 
undetectable when measuring total cortisol (59, 228). Measuring free cortisol is 
possible, but time consuming and cumbersome; therefore, this is rarely feasible in 
clinical practice. Several formulas for estimating the free proportion of cortisol have 
been published (51); these are less accurate as they will contain the variability in both 
the CBG and the cortisol analyses. 
The urinary free cortisol represents approximately 1% of the total cortisol secretion 
rate. The 24 h urinary free cortisol level has been used to evaluate overall cortisol 
load per day (157), but cannot be used to evaluate modern tailored twice or thrice 
daily dosage. Also, after an OHC dose CBG is rapidly saturated and the excess free 
cortisol secreted in the urine, which can give spurious results (190), especially if spot 
urinary samples are used. 
Salivary cortisol has the advantage of measuring the free cortisol, it is easy to use, and 
can be performed in an outpatient setting. There are caveats concerning pre-analytical 
errors, such as sample contamination from blood or OHC tablet residue; therefore 
patients should be instructed not to eat, drink, brush teeth or smoke the last hour 
before the sample is taken. The swab should be sufficiently soaked, either by chewing 
or keeping it in the mouth for 1-3 minutes. Elevated late night salivary cortisol is well 
validated as a marker for Cushing’s syndrome (229), but results from monitoring GC 
treatment are more conflicting. One study showed poor correlation between serum 
and salivary cortisol profiles both after oral and intravenous administration, as well as 
large inter- and intra-individual variability (230), and suggested together with others 
(231, 232) that salivary cortisol should not be used for monitoring GC replacement. 
Of note, these studies correlated salivary and serum total cortisol, which will increase 
58
the variability (50). Other authors have reported more promising results, and have 
suggested using salivary cortisol in clinical practice (233, 234). Of interest, in both 
studies claiming too high variability in salivary results patients were treated with 
OHC, and some of the samples were taken a short time (15 minutes) after OHC 
administration (230), which increases the risk of saliva contamination considerably. 
On the other hand, in the two studies reporting less variability, patients were treated 
with CA (233, 234), reducing the risk of contamination. A recent study showed very 
high salivary cortisol AUC levels in 31 AD patients receiving OHC treatment 
compared with matched controls (235), the largest variability in salivary cortisol 
levels were found in the first measurements after the oral morning dose. Taken 
together, OHC possibly gives more sample contamination than earlier perceived. 
By using liquid chromatography with sequential tandem mass spectrometry (LC-
MSMS) method for analysis of salivary cortisol, an accurate measurement of salivary 
cortisone can be obtained, and the up to 30% cross-reactivity for cortisone seen with 
most cortisol immunoassays can be eliminated (236). Conversely, LC-MSMS 
provides a much more reliable measurement of cortisone than immunoassays. Lately, 
salivary cortisone has been suggested as a more valid estimate for the unbound 
cortisol level in serum (50). Here, salivary cortisone had the highest correlation to 
measured serum free cortisol, and the authors proposed that salivary cortisone should 
be the preferred biomarker for serum free cortisol under basal and stimulated 
conditions, and also during OHC treatment.  
Another interesting analysis under investigation is hair cortisol content, as a recent 
study showed that hair cortisol content correlated with GC dose in patients with 
adrenal insufficiency (237). Previous studies have shown that hair cortisol is elevated 
in patients with Cushing syndrome, myocardial infarction, alcoholism and with 
increased stress (238-242). Hair grows approximately 1 cm per month, and a hair 
sample of the proximal 1 cm is thought to reflect the cortisol exposure over the last 
four weeks. Although this analysis is useless for the detection of cortisol variation 
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during the day and for identifying unphysiological cortisol peaks and troughs, the idea 
of having a biochemical marker of dosage over time in AD, similar to the use of 
HbA1c for glycaemic control in diabetes, certainly is appealing.  
Follow-up 
As AD is a rare disease with particular issues relevant for follow-up, we recommend 
annual controls at an endocrinology hospital clinic. Annual check-ups should include 
monitoring of the replacement therapy, reviewing episodes of potential or actual 
adrenal crises, repeating patient education if necessary and regular screening for 
concomitant autoimmune disease.  
As outlined above, the surveillance of GC replacement in clinical practice is currently 
based on clinical assessment (223). Too low GC doses increase the risk of adrenal 
crisis and reduced well-being, whereas too high doses increase the risk of 
complications such as osteoporosis, obesity and impaired glucose tolerance (108). 
Symptoms such as weight gain, abdominal obesity and peripheral oedema may 
indicate a too high daily dose, whereas symptoms like fatigue, myalgia or joint pain, 
nausea and anorexia may indicate under-dosage. Symptoms of both categories are 
unspecific, and hence an overall assessment of patient health is more important than 
isolated symptoms. Increased pigmentation due to high ACTH levels may suggest that 
doses should be increased; however, patients on conventional oral replacement 
therapy will invariably display elevated ACTH levels due to low cortisol levels during 
the night; hence some degree of pigmentation will usually persist. To evaluate the 
frequency of doses, asking the patients if they have low spots during the day is useful. 
If the patient is clock-watching for a particular dose this could indicate that the time 
interval between doses is too long and splitting the daily GC dose in more frequent 
doses should be considered. Morning fatigue or nausea indicates very low cortisol 
levels and possibly low glucose levels during the night. Some symptom relief could 
be gained by asking the patient to administer the morning dose 30-60 minutes before 
they get up, otherwise a small evening dose of prednisolone may be useful. In the 
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future, new treatment options which restore the nighttime cortisol levels can be useful 
for these patients. For patients on OHC who complains of “roller-coaster days”, 
switching to cortisone acetate could be a solution. Problems with sleep initiation can 
suggest that the last dose of the day is taken too late or is too high. Since reduced 
well-being or HRQoL is a characteristic feature of AD, an AD-specific HRQoL 
questionnaire could be of assistance in identifying problematic issues in individual 
AD patients.  
PRA is useful for monitoring mineralocorticoid dosage, aiming for PRA levels at or 
above the upper reference range to avoid too high doses (117). PRA levels reflect the 
mineralocorticoid dose better than sodium and potassium levels, but can be falsely 
elevated in GC overdosage, as GCs will increase the renin precursor angiotensinogen 
(243). Measuring orthostatic blood pressure and asking for dizziness are useful, as a 
drop in blood pressure in the erect position indicate clinically relevant 
mineralocorticoid deficiency. The presence of peripheral oedema suggests too high 
doses, and salt cravings suggest that the fludrocortisone dose should be increased. 
If DHEA treatment in females is tried, some authors suggest monitoring serum 
DHEAS, androstenedione, testosterone and SHBG, aiming at the middle normal range 
for healthy young people (108, 130). A clinical assessment of well-being, skin, pubic 
and axillary hair and possible androgen side-effects is of assistance (60).  
There are no international consensus guidelines concerning screening for concomitant 
autoimmunity in AD. Regular screening for thyroid disease and diabetes mellitus is 
generally recommended (130); in our practice this translates to measuring thyrotropin 
(TSH), free thyroxin (FT4), HbA1c and fasting morning glucose annually. If menses 
are irregular, screening for premature ovarian failure with antibodies against side 
chain cleavage enzyme should be considered in women; and if well-being and fatigue 
is present despite optimal replacement therapy, screening for vitamin B12 deficiency 
should be undertaken. Also, screening for celiac disease every five years is done at 
61
our centre. Routine BMD measurement is not recommended (108), but should be 
considered done at least once in patients with high GC doses or concurrent ovarian 
insufficiency.  
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3. AIMS OF THE STUDY 
Currently, the non-physiological cortisol levels resulting from conventional 
replacement therapy is suspected to be a major cause for the increased morbidity and 
the reduced HRQoL described in AD, although evidence is insufficient. In order to 
improve treatment and care for AD patients our aim was to develop a better tool for 
monitoring HRQoL and to improve the replacement therapy. Ultimately, we aimed to 
test whether a more physiological GC replacement would result in benefits over the 
conventional oral replacement therapy.  
Specifically, our aims were to: 
• Generate an AD-specific quality-of-life questionnaire apt for detecting changes 
in HRQoL status over time in AD patients.   
• Translate the original UK version to various European languages and to 
perform a large validation study. 
• Examine the construct validity, concurrent validity, reliability and 
repeatability, in order to improve and possibly shorten the questionnaire. 
• Test the final validated questionnaire in a large group of European AD 
patients.  
• Investigate whether CSHI in AD patients could mimic the physiological 
circadian cortisol rhythm and normalise ACTH levels (primary endpoint) 
• Investigate the effects of CSHI and OHC on GC metabolism and other 
metabolic parameters such as carbohydrate and bone metabolism; and effects 
on HRQoL and sleep (secondary endpoints). We also wanted to investigate 
whether CSHI was safe and well tolerated.  
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4. MATERIALS AND METHODS 
The AddiQoL 
Study design, Patients and Ethics 
The AddiQoL was developed by a multi-step approach involving initial generation of 
multiple relevant items and subsequent item reduction by expert evaluation and 
pretesting of items. The resulting questionnaire was translated to several languages, 
and all language versions were tested for validity and reliability, see below. 
For AddiQoL development, AD patients were recruited through the UK Addison’s 
disease self-help group. For validation, patients with verified AD were recruited 
locally from patient registries, or consecutively from outpatient clinics, in several 
countries. The patients received an invitation letter containing study information and 
the AddiQoL; by returning the pre-coded questionnaires they were included in the 
study. There were no exclusion criteria.  
The AddiQoL subject codes were used to retrieve patient characteristics such as age, 
sex and concurrent autoimmune diseases from registries, or via an additional pre-
coded registration form. To examine concurrent validity, the patients in Norway and 
Sweden also received the SF-36 and the PGWB questionnaires. For analysis of 
longitudinal reliability a subgroup of at least 20 clinically stable patients from 
Norway, Sweden and Italy completed AddiQoL a second time, 2-6 weeks after the 
first questionnaire. A random sample of 2000 persons with patient-matched sex, age 
and geographical distribution was drawn from the Norwegian People Registry. They 
received a letter with invitation to participate as control subjects by returning the 
completed anonymous AddiQoL questionnaire, with registration of age and sex only. 
The study was approved by Regional Ethics committees in each country. 
AddiQoL development 
HRQoL issues in AD were identified by literature search and in-depth interviews with 
UK AD patients and their partners (78). The list of items thus generated was reviewed 
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for clarity and relevance by nine expert clinicians and five experienced patients, and 
the number of items was reduced. The resulting preliminary questionnaire was tested 
in anonymous AD patients. The distribution in score for each item was examined; 
items with a narrow or skewed distribution were eliminated. If two items correlated 
significantly, one of them was considered redundant and eliminated. 
The resulting AddiQoL questionnaire containing 36 items (AddiQoL-36) was used for 
field-testing in 86 AD patients in the UK. For response categories, a six point Likert 
scale was chosen, ranging from 1 (none of the time) to 6 (all of the time) to indicate 
frequency, or 1 (strongly disagree) to 6 (strongly agree) to indicate severity. In items 
that were negative statements, the scoring was reversed; hence, a higher score indicate 
a higher HRQoL level. Furthermore, a preliminary analysis of validity and reliability 
was performed. 
Translation 
First, the AddiQoL-36 was translated into Norwegian, Swedish, German, Italian and 
Polish. The translations were performed locally in each country by a multi-step 
approach (78, 244). Preliminary translations were performed individually by 3-5 
members of the study group, each with good knowledge of the English language. 
After discussing each version, a panel of experts agreed upon a final version to be 
evaluated further. Two independent professional translators then assessed the quality 
of the translations and evaluated the conceptual equivalence with the original, the 
clarity and use of a familiar language. The professional translators both made 
suggestions to improve overall quality; their suggestions were re-evaluated by the 
study groups in each country, who decided upon a final version. Ultimately, large 
cohorts of AD patients in each country completed the final translated AddiQoL 
versions.  
Rasch analysis 
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The Rasch model rests on the idea that useful measurement involves examination of 
only one attribute at a time (unidimensionality). The model allows quantitative 
assessment (i.e. item scores can be added to a total score) from data that are ordinal, 
based on logistic transformation of the item responses (245). The objective is to test 
how well the observed data fit with the expectations of the mathematical 
measurement model (245, 246), which estimates how the patient group should have 
scored on each item if a logical hierarchical order is present for the items (91). If the 
observed patient scores do not fit with such a hierarchical pattern, validity is 
compromised. In lay terms, this translates to identifying at which HRQoL level each 
item provides the most information; and then organising the items in a hierarchy 
accordingly. If hierarchical ordering is present, the patients with the lowest HRQoL 
scores should be able to endorse the items covering the lowest HRQoL levels, but not 
the items covering a higher HRQoL level. Patients with a little higher HRQoL levels 
should be able to endorse both items covering the lowest HRQoL level, but also items 
covering a little higher HRQoL level, etc.  
Overall fit statistics examines fit to the model for both the items and the patients, 
calculated as mean item location and mean person location, and also include item-
person interaction statistics. Both person fit and item fit are transformed to 
approximate a z-score; this represents a standardized Normal Distribution. Therefore, 
if the items and persons fit the model perfectly, the mean Fit Residual is expected to 
be zero with standard deviations around 1. Overall fit statistics also includes Ȥ2
statistics for item-trait test-of-fit to the model. This tests whether the items work as 
expected at group level along the range of the scale. A non-significant Ȥ2 probability 
implies that the hierarchical ordering of items and persons do not vary across the 
range of the scale (247).  
A practical consequence of the fit statistic is that problematic items can be identified 
and eliminated to improve the validity of the questionnaire. Any item with a fit 
residual greater than +/- 2.5 is a cause for concern; a high positive item fit residual 
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indicates that the item does not separate well between high and low person ability (or 
HRQoL), and a high negative item fit residual indicates redundancy or local 
dependency (see below) of the item. Other causes of misfit to the Rasch model are 
disordered thresholds and differential item functioning (DIF), that is, item bias (246). 
A threshold is the point where the probability of endorsing two neighbouring response 
alternatives is equal; one threshold exists for each transition between one scoring 
alternative and the next. To obtain ordered thresholds, each item and response 
alternative is assessed, and collapsed or rescored when necessary. This can improve 
item fit and the validity of an item. DIF analysis explores item performance and 
questionnaire performance across different patient groups. DIF exists if one patient 
group scores significantly different on an item compared with another patient group 
with similar overall HRQoL level (246). For example, if an item works differently in 
men and women, this item would give a different contribution to the total score in 
men when compared with women. This would compromise validity of the 
questionnaire. However, if two items contain DIF for the same person factor, it is 
possible to group these to items together as a combined item. If DIF disappears in the 
combined item, the detected DIF do not compromise the validity of the total score of 
the questionnaire.  
Each item’s difficulty (item location) and each person’s ability (person location) are 
organized in ordered hierarchies (245, 248). By plotting item location and person 
location on the same scale, the targeting of the items to the sample population can be 
explored. A perfect targeting is indicated if average person location is zero. 
To produce a psychometrically meaningful total score, the scale has to be 
unidimensional (245). Fit to the model and an absence of a significant pattern among 
the Fit Residuals supports the scale being unidimensional, i.e., there is only one 
concept being measured. Local dependency exists when there is covariance between 
the response pattern of items, and this is considered a breach of the strict 
unidimensionality that the Rasch model requires. This can be corrected for by 
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grouping items with covariance together, i.e. treating the item group mathematically 
as a single combined item (249). 
In Rasch analysis, the Person Separation index (PSI) is equivalent to the reliability 
coefficient (Crohnbach’s Į), and represents the power of the construct to discriminate 
between respondents (247). PSI is calculated as the ratio of true variance to observed 
variance and represents the proportion of variance that is not due to error (247, 248). 
A PSI of 0.85 is generally required if the scale is to be used on the individual level. 
Examining validity and reliability 
To examine the construct of the questionnaire, the responses from the patients were 
first analyzed by exploratory factor analysis (EFA), the purpose being to identify 
items that do not correlate with the rest of the items in the questionnaire. The 
construct validity was further explored applying Rasch analysis, to identify 
problematic items compromising validity and to investigate the psychometric 
measurement quality of the questionnaire. All analyses were performed for individual 
countries as well as for the pooled data. 
The overall fit statics including individual person- and item fit and item-trait 
interaction was evaluated by Ȥ2 statistics incorporated in the RUMM2020 software. 
Misfitting items were identified and considered for elimination. Thresholds were 
examined and response categories collapsed and rescored if thresholds were 
disordered. To identify item bias we examined DIF with regard to patient sex, age, 
country and concurrent autoimmune disease. If DIF was present for a person factor, 
we considered either splitting of the item or grouping the item with another item with 
DIF in the opposite direction, otherwise the item was eliminated. Local dependency 
was identified by examination of correlation of the fit residuals. If local dependency 
was present, mathematical grouping of the affected items in to a “super-item” was 
considered. Unidimensionality was assessed by identifying items loading positively 
and negatively on the first principal component of the residuals. Person estimates 
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from these to item groups were compared by independent T-tests incorporated in 
RUMM2020. If less than five percent of the T-tests were found significant different, 
the questionnaire was considered unidimensional. Targeting of the items to the 
distribution in person scores was evaluated by comparing person location and item- or 
threshold location. 
The reliability coefficient Cronbach’s Į and PSI were calculated for the pooled data, 
and PSI was also calculated for individual countries. Longitudinal reliability was 
examined by comparing scores on two occasions in the same clinically stable sample.  
A test-retest DIF analysis was performed for patient subgroups with stable clinical 
condition in Norway, Italy and Sweden, over two to six weeks’ intervals.
Concurrent validity was examined by comparing AddiQoL scores with SF-36 and 
PGWB scores in Norway and Sweden. Spearman’s ȡ with two-tailed significance was 
calculated for the correlation analysis. The Mann-Whitney U-test was used to 
compare Norwegian patients’ AddiQoL scores with AddiQoL results from a random 
Norwegian population sample. However, for disease-specific questionnaires 
comparisons between patients and normative data from a reference population should 
be interpreted with caution, as items are optimized for specific patients groups.  
Comparison of HRQoL scores in different subgroups of patients was performed by 
multiple linear regression analysis with sex, age, country and comorbidity as 
independent variables. 
The clinical trial 
Study design, Patients and Ethics 
The clinical trial was designed to prospectively compare the effects of mimicking the 
physiological circadian cortisol rhythm by CSHI to the effects of conventional OHC. 
As AD is rare, a multi-centre study was necessary to recruit enough participants. After 
discussing realistic recruitment possibilities and statistical considerations, a cross-
over study design was selected. A treatment period length of three months with each 
treatment type was considered long enough to be able to detect relevant changes in 
69
endpoints; and a between treatment wash-out period of minimum eight weeks enough 
to minimise the risk of carry-over effects.  
The patient registry (ROAS, Registry of Organ specific Autoimmune Diseases) or the 
hospital diagnosis registries were used to identify eligible AD patients. Patients who 
fulfilled the inclusion and exclusion criteria and signed the consent form were invited 
to a screening visit, where they participated in a practical group course on pump 
treatment. The patients then underwent a period of dose adjustments (see below) of 
both treatments (OHC and CSHI). The investigators considered withdrawal for safety 
reasons if a patient had major difficulties managing the infusion pump. Thereafter, the 
patients were randomized to either treatment sequence with fixed individual doses of 
CSHI and OHC. A flow-chart describing patient screening, inclusion and withdrawal 
are presented in figure 8.  
70
The study was approved by Regional Ethics committees and the National Medicines 
Agencies in both countries (EudraCT # 2009-010917-61). We conducted the study in 
accordance with the principles of Good Clinical Practice (CPMP/ICH/135/95) and the 
Declaration of Helsinki on ethical principles for medical research involving human 
subjects (1989 version).  
Intervention 
The CSHI dosing algorithm was derived from the pilot trial (222). A proposed CSHI 
dose and dose interval was created based on the estimated normal endogen cortisol 
production (193, 194), and tested in patients while repeated measurement of salivary 
cortisol was performed. The results suggested a starting dose of 10 mg/m2/d divided 
in four dosing intervals: h 08:00-12:00, 0.5 mg/m2/h; h 12:00-20:00, 0.2 mg/m2/h; h 
20:00-02:00, 0.05 mg/m2/h; h 02:00-08:00, 1.0 mg/m2/h.   
For the current trial, we used the dosing recommendations and the four dosing 
intervals as suggested in the pilot trial. Some of those patients had complained of low 
energy levels at the end of their working day, suggesting that the dose was too low at 
that time point. Therefore the first dosing interval was prolonged two hours (h 08:00-
14:00) in the current study, producing an increase in the suggested starting dose to 
10.5 mg/m2/h, see figure 9. Thus, the daily CSHI starting doses was adjusted to body 
size, and furthermore individualized during a period of dose adjustment prior to 
randomisation.  
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Since CSHI is technically more complicated than OHC, patient education had to be 
secured before randomisation. At the screening visit, the patients attended a practical 
group course on pump treatment, led by an experienced diabetes nurse, with long 
experience in teaching diabetic patients continuous subcutaneous insulin infusion. 
Here, the patients learned the proper procedure for self-injections, how to mix the 
Solu-Cortef act-o-vial and how to fill the pump and injection gear with 
hydrocortisone. They were also taught how to program the pump with the correct 
doses, and how to check for treatment malfunction such as battery failure and leakage, 
and how to check if there was enough hydrocortisone left in the pump. They were 
instructed to replace the injection gear and refill the pump every third day. Because of 
the immunosuppressant effects of hydrocortisone, we advised the patients to clean the 
injection site with alcohol prior to an injection. They were instructed to contact the 
investigator if signs of infection developed. CSHI doses were evaluated by measuring 
morning salivary and serum cortisol and late evening salivary cortisol, aiming for 
normal levels.  
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For the oral treatment, we chose thrice daily OHC, partly because this is the drug of 
choice in most countries, and partly because we wanted to achieve a comparator 
treatment as physiological as possible with conventional treatment. The OHC dose 
algorithm suggested by Mah et al. was chosen to secure that also OHC doses were not 
too high, that they were individually adjusted, and adjusted to body size (151).  
For both treatments, we allowed smaller dose adjustments at the discretion of the 
investigators based on best clinical judgment during the dose-adjusting period. 
Glucocorticoids, ACTH and CBG 
Morning plasma ACTH, serum cortisol and CBG were measured at baseline, eight 
weeks and 12 weeks in each treatment arm.  
Twenty-four hour urine cortisol, cortisone and their metabolites were measured once 
during each treatment type, and used to calculate indices of enzyme activity. Overall 
11ȕ-HSD activity was calculated as (THF + allo-THF)/THE, 11ȕ-HSD2 activity as 
cortisone/cortisol, 5Į-reductase activity as allo-THF/cortisol, 5ȕ-reductase activity 
(reduction of cortisol) was calculated as THF/cortisol, 5ȕ-reductase activity 
(reduction of cortisone) as THE/cortisone, and CYP3A4 activity as 6ȕ-OH-
cortisol/cortisol.  
Circadian salivary cortisol and cortisone were sampled twice within each treatment 
period, at hours 08:00, 09:30, 11:00, 12:30, 14:00, 15:30, 17:00, 18:30, 19:00, 21:00, 
24:00, 03:00 and 06:00. The patients were asked to take their prescribed OHC doses 
at hours 08:00, 12:30 and 17:00 on the days when the salivary samples were collected. 
The area under the curve (AUC) was calculated by the composite trapezoidal rule, 
and reported for 24 hours (AUC24h) as well as for daytime (AUC08-24) and nighttime 
(AUC24-08) for each patient and for each treatment arm. 
Metabolic parameters 
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At each visit, measurements of blood pressure, weight, waist and hip circumference 
were measured, and body mass index (BMI) and waist-hip ratio (WHR) calculated. 
Fasting blood samples were drawn at 08:00 at baseline and after 8 and 12 weeks on 
each treatment. The samples were stored at -80ƕC until the end of trial. Carbohydrate 
metabolism was assessed by measuring morning glucose, insulin and insulin C-
peptide. The insulin resistance (homeostatic model assessment; HOMA) index was 
calculated as fasting plasma glucose (mmol/L)* fasting serum insulin (mIE/L)/22.5) 
(250). Samples suited for HbA1c analysis were available only for 14 Norwegian 
patients. Serum total cholesterol, high-density lipoprotein (HDL), low-density 
lipoprotein (LDL) and triglycerides were measured. To investigate impact on bone, 
we measured the bone formation marker procollagen type 1 N-terminal peptide 
(P1NP) and the bone resorption marker C-terminal crosslinked C-telopeptide of type 
1 collagen (CTX-1). 
HRQoL 
At each visit, the patients completed three HRQoL questionnaires: the SF-36, the 
PGWB and the AddiQoL (appendices 1, 2 and 3). The SF-36 and the PGWB scores 
were calculated and presented as recommended. The AddiQoL comprised 30 items 
with six response options, which were scored 1, 2, 2, 3, 3 and 4, according to the 
results of the AddiQoL validation study. The score of the negative statement items 
were reversed before calculating a total score; thus, a higher score indicates a higher 
HRQoL level. Also, the score of the eight-item AddiQoL short version was calculated 
in the same manner (appendix 4). The resulting AddiQoL score range from 30 (lowest 
possible HRQoL level) to 120 (highest possible HRQoL level), and the AddiQoL 
short version score range from 8 to 32.  
Sleep 
To measure subjective sleep quality during the last month the patients completed the 
Pittsburgh Sleep Quality Index (PSQI) at each visit (appendix 5). The PSQI consists 
of 16 items producing seven component scores as well as a total index ranging 0-21 
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(251). A higher score indicates more sleep problems and a score above 5 is indicative 
of poor sleep quality. For objective sleep registration, the study participants 
completed a 7-day actigraph registration a minimum of eight weeks after baseline 
during both CSHI and OHC treatment. Concomitantly a sleep diary (appendix 6) for 
the period was administered. The actigraph continuously records information about 
intensity and frequency of movement using an accelerometer. The following variables 
were chosen for analysis: time in bed, sleep time, wake time, sleep efficiency, sleep 
onset latency, sleep bouts, wake bouts and sleep fragmentation. 
Circadian study 
The 10 first Norwegian patients (the circadian group) were included in an extended 
protocol and admitted twice, i.e. during OHC and CSHI treatment at approximately 8-
12 weeks, to a clinical research facility for 24 h blood sampling. The aim was to 
determine whether circadian cortisol rhythm was restored, and to analyze the 
circadian effects on ACTH levels. The AUC for serum cortisol was calculated. Also, 
the effects on metabolic fuel were assessed by 24 h glucose and insulin levels and 
triglyceride levels during the night. Nighttime levels of growth hormone, insulin-like 
growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP3) 
were also investigated. Serum and plasma samples were collected hourly from an 
indwelling catheter in a forearm vein; ACTH was sampled every three hours. During 
OHC the patients administered their medication at 08:00, 12:30 and 17:00 while 
admitted. 
Euglycaemic clamp  
All the fifteen Swedish patients (the insulin sensitivity group) were admitted twice, 
i.e. after eight weeks of each treatment, for euglycaemic-hyperinsulinaemic clamp 
according to De Fronzo et al. in a fasting state during the morning hours (252). 
Intravenous catheters were inserted into the right arm for substrate (insulin/glucose) 
infusion. During the 120 min of the test, insulin (Actrapid [40 mU * m2(−1) * min−1], 
NovoNordisk A/S, Copenhagen, Denmark) was infused together with 20% dextrose 
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(Fresenius Kabi, Stockholm, Sweden). The rate of dextrose infusion was adjusted to 
achieve a blood glucose level of 5.0 mmol/L based on arterialized samples withdrawn 
every five minutes from an ipsilateral dorsal hand vein. Whole-body insulin 
sensitivity (M-value) was calculated from the amount of glucose infused during the 
last 30 min of the clamp divided by body weight (kg) and period (min) and expressed 
as mg/kg/min. Serum cortisol and cortisone were measured every 30 min during the 
euglucaemic-hyperinsulinemic clamp. 
Statistics 
Data were presented as percentages, medians or means together with a variability 
measure such as standard error or confidence interval. All p-values were two-sided 
and values less than 0.05 were considered statistically significant. The AUC24h for 
salivary and serum profiles was calculated by the composite trapezoidal rule, and for 
salivary samples also reported for daytime (AUC08-24) and nighttime (AUC24-08) for 
each patient and for each treatment arm. Statistical analysis of paired data (24 h urine 
and AUC analyses in Paper 3 and euglycemic clamp in Paper 4) was done by 
Wilcoxon signed rank non-parametric test for related samples. 
To estimate differences in metabolism, HRQoL and sleep between CSHI and OHC 
treatments a linear mixed effects model for repeated measures was used (253). Our 
model defined treatment, visit time, treatment sequence, treatment period and 
treatment-by-time interaction as fixed effects. To account for the intra-individual 
correlation between repeated measures a random effect with patients nested within 
sequence of treatment was specified. Because of skewed distributions, several 
variables from the SF-36 domain, glucose, HOMA-index and CTX-1 were 
transformed according to recommendations before model testing (254). 
To investigate a treatment-by-time effect on metabolism, HRQoL and sleep we used 
the likelihood-ratio test by comparing the log-likelihood between models with and 
without the treatment-by-time term. To obtain p for trend in means within treatment 
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groups the effect of time was included as a linear term in the mixed effect model 
using the z-test. To obtain p for model-predicted mean differences between treatment 
groups for different visit time we performed a post-hoc test for pairwise comparisons 
(z-test).  
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5. RESULTS AND SUMMARY OF PAPERS 
Paper 1 
Paper 1 describes the development of AddiQol, and reports the initial results of its 
reliability and validity. A list of 70 items relevant for AD was generated; after 
revision the number was reduced to 60 items, which was pretested in 100 AD patients 
in the UK. The number of items was further reduced to 36 after scrutinising each item 
for distribution of scores, relevance, redundancy, and possible sensitivity. The 
resulting 36 item AddiQoL questionnaire was then tested in 86 AD patients in the 
UK.  
The AddiQoL-36 displayed a high reliability with a Crohnbach’s alpha of 0.95 and a 
Pearson Separation index (PSI) of 0.94. Rasch analysis suggested some misfitting 
items with item fit residuals above 2.5. Overall, there was a misfit to the Rasch model 
of the total 36 items (item-trait interaction Ȥ2 <0.0001), but exclusion of six items with 
extreme fit residuals improved fit to the Rasch model (item-trait interaction Ȥ2 >0.09) 
to an acceptable level. The difficulty of the items (item location) gave a satisfactory 
coverage of the distribution of patient scores (patient location) with no apparent floor 
or ceiling effect, indicating overall good targeting of the items to this patient group. 
Because of the relatively small sample size, it was difficult to draw any firm 
conclusions regarding misfitting items and revision of the questionnaire; therefore all 
36 items were kept pending a larger validation study.  
Paper 2 
Paper 2 reports the results of a large European AddiQoL validation study. A total of 
615 patients were recruited from registries or outpatient clinics in Norway (n=107), 
Sweden (n=101), Germany (n=200), Italy (n=157) and Poland (n=50), and completed 
the AddiQoL-36. The data was pooled with the original UK data (n=86). Reliability 
and validity were assessed for all countries pooled together, as well as for individual 
countries. 
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EFA showed that the items could be grouped in four domains; eight items covered 
energy level (sub-dimension Fatigue), eight items covered emotional or mental 
aspects (Emotions), 11 items common AD symptoms (Symptoms), and six items basic 
aspects like sleep, sexuality and impact of intercurrent disease (Miscellaneous). Three 
items did not fit into any domain, their misfit was confirmed with subsequent Rasch 
analysis, and they were therefore eliminated. The Rasch analysis revealed three 
additional problematic items, which were eliminated. 
Disordered thresholds were present, indicating that the patients had problems 
differentiating between the six scoring categories (1, 2, 3, 4, 5, 6). Collapsing the 
middle adjacent response options by rescoring categories (1, 2, 2, 3, 3, 4) resulted in 
ordered thresholds and improved fit to the Rasch model.  
There was no significant DIF between the genders, and no DIF when comparing the 
results from patients with isolated AD with patients with autoimmune polyendocrine 
syndromes. Significant DIF for age was present in the Emotions sub-dimension. 
Significant DIF for country was present in the Fatigue, the Symptom and the 
Miscellaneous sub-dimensions. 
The 30 remaining items arranged in the four sub-dimensions fitted the Rasch model 
(item-trait interaction Ȥ2 p=0.56) and proved unidimensional. Person-item targeting 
was good in all countries.  Reliability was high as Cronbach’s Į was 0.93 and PSI 
0.86. Test-retest reliability was excellent; no item bias for time was detected in 
clinically stable patients in Norway (n=37), Italy (n=25) and Sweden (n=29).  
Correlation between the AddiQoL scores and concurrent scores for the PGWB and 
SF-36 subdimension scores Vitality, General Health and Physical Function were high 
in Norwegian and Swedish patients. The AddiQoL scores were significantly lower in 
AD patients (p<0.001) than in a random population sample (n=539) in Norway. 
Regression analysis revealed that women scored worse than men (p<0.001), and the 
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scores worsened with increasing age (p<0.001). No difference was found between 
patients with isolated AD and those with polyendocrine syndromes.  
In conclusion, the AddiQoL was translated to five European languages, the number of 
items reduced to 30 and the item scoring range altered, resulting in a psychometrically 
valid and reliable AddiQoL questionnaire. This study design did not provide an 
opportunity to further test the responsiveness of the AddiQoL. Also, an AddiQoL 
short version (i.e. the Fatigue dimension) was produced; suitable for use when 
measuring fatigue is the main objective. In patients without fatigue, the short version 
could be less sensitive to change due to ceiling-effects, as the short version displayed 
less optimal item-person targeting when compared to the AddiQoL. 
Paper 3  
Paper 3 reports the results of the randomised controlled cross-over clinical trial 
“Glucocorticoid treatment in Addison’s disease” as per study protocol (NCT 
01063569). Thirty-seven patients were randomised, and 32 completed the trial. 
Results from both treatment arms were available for 33 patients (see Figure 8). The 
mean patient age was 48 (SD 12) years, the mean AD duration 12.4 (SD 10.1) years, 
and 25 patients (75.8%) were female. The OHC doses (mean 0.26 mg/kg/d; SD 0.08) 
were slightly lower than the CSHI doses (mean 0.31 mg/kg/d; SD 0.07); both were 
lower than the hydrocortisone equivalent pre-trial doses (mean 0.36 mg/kg/d, SD 
0.13). 
CSHI brought the morning ACTH levels back to normal, contrasting the very high 
levels seen with OHC. CSHI also normalized the morning cortisol levels, and 
produced 24 h salivary cortisol and cortisone day curves resembling the normal 
circadian variation including the late night cortisol surge. In contrast, OHC produced 
the typical daytime supra-physiological post-dose cortisol peaks followed by troughs 
before the next dose. Nighttime and early morning cortisol levels were very low. 
There was no between-treatment difference in salivary cortisol AUC24h, but salivary 
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cortisone AUC24h was higher with CSHI. Effects on other metabolic parameters were 
generally small, with the exception of significantly higher morning glucose on CSHI 
than on OHC. No between-treatment difference was found for insulin, insulin C-
peptide or HOMA-index. There were no between-treatment difference in blood 
pressure, weight, WHR or BMI, and no difference in cholesterol, HDL, LDL or 
triglycerides. Effects on bone markers and between-treatment differences were small, 
and the CTX-1 and P1NP means were within the reference range on either treatment. 
However, both CTX-1 and P1NP declined significantly during CSHI treatment, 
whereas during OHC treatment P1NP increased without changes in CTX-1.  
CSHI did not significantly affect sleep compared to OHC, but might have positive 
HRQoL effects. CSHI increased AddiQoL and AddiQoL short version scores, 
whereas no effect was found for OHC, and AddiQoL scores were significantly better 
for CSHI than for OHC. CSHI yielded significantly superior scores in the SF-36 
physical function scale and the PGWB vitality score. The other subscales of both 
generic questionnaires detected no changes and no between-treatment differences, 
implying that the AddiQoL is better apt to detect changes in HRQoL in AD than the 
generic questionnaires.  
Paper 4 
Paper 4 reports the results from two sub-populations of the study in whom circadian 
hormone levels and metabolic effects were studied in more detail.  
In the circadian group, the median hydrocortisone dose was 0.28 mg/kg/d (range 0.20-
0.50) and 0.23 (0.25-0.50) mg/kg/d for CSHI and OHC treatments, respectively. 
CSHI yielded a smooth circadian cortisol curve, with mean serum cortisol within the 
reference range for healthy individuals, including the physiological low evening 
levels and a late night cortisol surge culminating in an early morning peak. In 
contrast, OHC brought about low nighttime cortisol levels and high post-dose peaks 
followed by troughs. The median serum cortisol AUC24h was higher for CSHI than for 
81
OHC (p=0.028). Furthermore, ACTH levels remained clearly elevated with OHC, 
contrasting the near normal circadian levels found with CSHI.
  
On OHC, the patients had gradually decreasing glucose levels during the late night, 
with the lowest levels at h 08:00. During CSHI treatment, the glucose nadir was 
observed at h 02:00. A further decrease in glucose levels was avoided, resulting in 
improved mean serum glucose level during early morning when compared with OHC. 
Differences in 24 h serum insulin levels were generally small. Twelve-hour nighttime 
measurements of triglycerides were in the normal reference range and did not differ 
between the two therapies. 
During both treatments there was a GH peak during the first part of the night, which 
during CSHI tended to be more pronounced than during OHC. For IGF-1 there was a 
trend for higher levels at each hour in the CSHI group with a significant difference at 
h 01:00 and h 08:00. The IGFBP3 was significantly higher with CSHI at h 08:00, 
09:00 and h 12:00, correlating with the IGF-1 peak in the CSHI group at h 08:00. 
In the insulin sensitivity group the median hydrocortisone dose was 0.27 mg/kg/d 
(0.24-0.35) for CSHI and 0.23 (0.21-0.32) mg/kg/d for OHC treatment. No difference 
was noted in insulin sensitivity (M-value) between treatment groups (p=0.59) for the 
CSHI and OHC treatment. There was no difference in cortisol and cortisone at 0 and 
30 min during the clamp, but both cortisol and cortisone were significantly higher at 
60, 90 and 120 min in the CSHI-treated group. 
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6. GENERAL DISCUSSION 
AddiQoL 
AddiQoL development 
The development of the AddiQoL provided a valid and reliable AD-specific 
questionnaire, which will hopefully become useful for detecting changes in HRQoL 
in patient groups or individual patients over time. The multi-step approach of item 
generation and reduction secured a satisfactory breadth of HRQoL range coverage for 
AD patients, which is essential for a disease-specific questionnaire. The resulting high 
reliability and validity secures that changes in AddiQoL scores obtained over time, or 
differences found between patients groups, can be trusted. Retrospectively, testing for 
threshold ordering revealed that the chosen 6-point Likert scale did not fit all items. If 
Rasch analysis had been applied earlier in the development process, this might have 
been avoided.   
Methodological considerations
Rasch analysis is increasingly used in somatic medicine and endocrinology, and was 
previously applied in the validation of QoL-AGHDA (255), AcroQoL (256) and 
CushingQoL questionnaires (95). We chose Rasch analysis to explore the 
psychometric properties of AddiQoL, that is, to examine construct validity, because 
fit to the Rasch model confirms that basic properties of a measurement instrument are 
secured, such as hierarchical ordering and unidimensionality. These properties should 
be present to allow adding the score of individual items to a total score. The Rasch 
model also allows the researcher to examine the measurement properties for 
individual items, which we found extremely useful in the process of validating the 
AddiQoL. The opportunity to examine how well the item location target the patient 
location is valuable; here we could demonstrate how well the items as a group target 
the distribution of HRQoL scores in the patient group, which is an important issue for 
a disease-specific questionnaire. 
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High reliability and good discriminating properties usually indicate good evaluative 
properties (responsiveness) as well. However, the items with the best fit to the Rasch 
model might not necessarily be the items most sensitive to change (257). Clinical 
issues such as disease-specific symptoms, might not have the best fit to the stringent 
Rasch model, yet such items are important to include in evaluative disease-specific 
questionnaires as they are expected to be more responsive to change during disease 
intervention. Also, while high reliability indicates a high signal to noise ratio, a too 
high reliability might compromise responsiveness of the questionnaire (257). 
Reliability may also be inflated by the presence of redundant items or items with local 
dependency (245). Therefore, the validation process had to secure a balance between 
retaining highly relevant items without compromising the basic psychometric 
requirements of a measurement instrument. 
The rescoring of response options in the AddiQoL reduced the score range of the 
questionnaire, which possibly reduces responsiveness of the AddiQoL. However, this 
was necessary as the disordered thresholds found initially indicated that basic 
hierarchical ordering was not present. In this situation a score change from response 
option two to response option three might be random and not represent real HRQoL 
change. Rescoring the response option secured that basic hierarchical ordering now is 
present, rendering the detection of a small change in HRQoL score more reliable. 
We detected DIF between countries, indicating that several items functioned 
somehow different in different countries, which is common for HRQoL 
questionnaires. Whether this is due to small translational differences, cultural 
differences or other issues such as differences in patient characteristics cannot be 
clarified. If the aim is to compare HRQoL scores between countries, the biased items 
will have to be statistically adjusted for each country before comparisons can be done 
(258). However, the country DIF may have a negligible clinical impact when 
evaluating the HRQoL scores from a multicentre clinical trial (259).  
Future perspectives 
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A challenge to HRQoL measurement in clinical practice is the interpretability of the 
HRQoL score. Even if scores do significantly improve or deteriorate over time, how 
are this interpreted to give meaningful clinical information about the HRQoL change?  
The minimal clinically important difference (MCID) is defined as the smallest 
difference a patient will perceive, that would mandate a change in clinical 
management (260). Whenever the detected difference in mean scores is less than 
MCID, the difference is considered not clinically relevant. The MCID can be 
calculated by an anchor-based approach, i.e., by linking the difference in HRQoL 
scores found in a trial to a clinically relevant endpoint, to the results of a symptom 
score, or to patient opinion of whether the detected change is clinically relevant. This 
approach has been criticised for being imprecise, but has nonetheless been useful for 
several disease-specific questionnaires (261, 262). Alternatively, the MCID can be 
calculated by a distribution-based approach. Some authors suggest calculating MCID 
as half the standard deviation at baseline, although this is controversial (263, 264). 
Another possibility is to calculate the effect size, i.e. to compare the HRQoL change 
over time to the standard deviation at baseline (265). Presently, the most common 
distribution-based approach is to define MCID as one standard error of the mean 
(SEM) (266). Ideally, the MCID should be calculated by several approaches, as 
results may vary between methods (266, 267). The use of one cut-off value for the 
MCID has been criticised, as it is based on mean changes in one patient group, and 
also because the meaning of a HRQoL change depend on the starting point and on the 
direction of change (268).  
To demonstrate responsiveness, it is necessary to identify AD patients who truly 
change, and compare their AddiQoL results to HRQoL scores with scores in patients 
who do not change. Compared to other endocrine diseases such as acromegaly or 
growth hormone deficiency, it is difficult to sample HRQoL in untreated AD patients 
as AD treatment has to be started without delay. Hence, to demonstrate 
responsiveness and define MCID we rely on demonstrating differences in HRQoL 
scores between different treatment types, and the detected difference in HRQoL 
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scores will therefore be smaller. In AD, there is no clinical endpoint or physical test 
available for anchor-based definition of MCID. We have correlated our results with 
the best “gold-standard” available, and shown that the AddiQoL detected improved 
HRQoL levels with CSHI, whereas with SF-36 and the PGWB differences were 
smaller and significant only on a few subscales. Future studies on responsiveness are 
needed for the AddiQoL, and should possibly include both estimation of the MCID 
and calculation of the responsiveness index (269).   
Since new and more expensive AD treatment options are under development, it may 
become important to better define what constitutes a clinical relevant increase in 
AddiQoL score. From the view of a health economist, the cost-benefit balance of new 
treatment options should be considered, and a benefit in HRQoL documented by the 
AddiQoL could possibly be used for these kinds of calculations in the future.  
Future application of the AddiQoL depends on the availability of translations to 
relevant language versions. We know from personal communications that Danish, 
Spanish and Japanese versions have been created, although no validation studies have 
been published yet. To encourage the use of AddiQoL, it is free to use, and new 
language versions are welcomed.  
Pump treatment in AD  
CSHI dosing and monitoring 
Because the administration mode of hydrocortisone is different with CSHI and OHC, 
we could not assume equal daily doses in the two conditions. The dosing algorithms 
applied in our study were different for the two treatment types, and resulted in slightly 
higher daily doses of hydrocortisone with CSHI than with OHC, although both the 
OHC and the CSHI doses were reduced compared with pre-trial doses. However, the 
main difference between treatments was the dissimilar circadian distribution of the 
daily dose. The AUC24h for salivary cortisol did not show significant between-
treatment differences, but the AUC24h for salivary cortisone were significantly higher 
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with CSHI than with OHC. Salivary cortisone may better reflect the free serum 
cortisol levels in serum (50), suggesting a higher cortisol bioavailability with CSHI 
than with OHC. The elevated 24 h urine cortisol and cortisone levels found with 
CSHI are in line with this (see below).  
However, we did not find any proof of overdosage with CSHI; while there was a 
trend towards increasing BMI with CSHI, there was no significant between-treatment 
difference. Likewise, there was a significant trend towards higher morning HOMA- 
index with CSHI, but no between-treatment difference was found. In addition, as no 
between-treatment in insulin sensitivity was detected with euglucaemic clamp, the 
trend towards increased morning HOMA-index was probably due to the timing of the 
glucose and insulin samples in the morning when cortisol levels were much higher 
with CSHI than with OHC. The fact that HbA1c levels decreased with both 
treatments and that no changes were found in other parameters such as WHR, blood 
pressure or lipids was also reassuring.  
In contrast to diabetic patients, AD patients are not as experienced in self-injections or 
the mixing of drugs for injection. Hence, proper education of both the patient and 
health care professionals are mandatory before starting CSHI treatment. One worry 
prior to starting this trial was the risk of local infection at the injection site. We 
experienced no adverse events due to local infections during the trial. Another 
concern was that AD patients have no means to monitor if the pump treatment is 
working as expected, whereas diabetic patients can rely on glucose levels to monitor 
if insulin is delivered as expected. With CSHI, we had to rely on indirect signs such 
as the decreasing amount of drug in the pump, no leakage, and most importantly the 
well-being of the patient. During the trial, the patients reported that they were 
reassured by hearing the pump deliver the drug every fourth minute. Experience from 
the dose adjustment period taught us that it was practical to use the pump program to 
check which dose had been delivered the previous day, to check if everything was 
working properly. Checking the refill dates and alarm history also proved helpful in a 
87
few patients. Patients were instructed to use extra oral doses of their pre-trial drug if 
they felt unwell, and to contact the investigator as soon as possible.  
Pump treatment also has other potential positive sides, which we did not explore in 
this study. Vomiting or diarrhoea is the most common precipitating cause of adrenal 
crisis in AD patients (132). With parenteral replacement like CSHI the risk of AC 
might be reduced in these situations. The pumps can also deliver extra hydrocortisone 
boluses if needed, and the size of the dose can be lower than feasible with the current 
oral replacement drugs. Increased dosage can also be delivered by temporarily 
increasing the basal rate of the infusion, for example by doubling the infusion rate 
during days with febrile illness, or increase the basal rate to 150% during strenuous 
exercise. 
Salivary cortisol or cortisone is useful in monitoring CSHI treatment. However, in the 
trial we detected a few results with extremely high salivary cortisol levels (above 
1000 nmol/L), most likely a result of pre-analytical error. The cortisol concentration 
in Solu-Cortef is substantially higher than in saliva, and even small amounts of Solu-
Cortef contaminating the saliva swab will result in extremely high salivary cortisol 
results. With this exception, our results indicate that CSHI can be monitored by 
morning and late evening salivary cortisol samples, or day curves. We recommend 
aiming for morning salivary cortisol in the middle reference area, and evening 
salivary cortisol within the reference area (< 2.8 nmol/L) for optimal dosage. If the 
patient is not feeling well, measuring morning serum cortisol in the normal reference 
range can exclude under-dosage, and measuring a morning ACTH at the upper 
reference range can reassure that doses are not too high.   
Effects on cortisol metabolism 
The higher AUC24h for salivary cortisone found with CSHI suggests that the free 
cortisol levels were higher than with OHC (50). In addition, the 24 h urine cortisol 
and cortisone were significantly higher with CSHI than OHC. Also, the circadian sub-
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study revealed that after the dose increase at h 02:00, cortisol levels increased faster 
than expected from the pilot trial, suggesting that this dose interval could preferably 
be delayed. As a consequence, we suggest postponing this dose interval by one hour, 
i.e. to h 03:00-08:00, hence lowering the CSHI starting dose to 9.55 mg/m2/d.  
Furthermore, the indices for 11ȕ-HSD2 activity, CYP3A4 activity, ȕ-reductase 
activity and Į-reductase activity were all lower with CSHI than with OHC. There was 
no between-treatment difference in overall 11ȕ-HSD activity. When comparing our 
results with those from control persons in a recently published study we found that 
OHC increased all these enzyme indices, whereas CSHI restored them closer to 
normal. However, the high 24 h urine cortisone level seen with CSHI complicates the 
interpretation of the estimated index for 11ȕ-HSD2 activity, as this enzyme has 
nonlinear kinetic properties (67, 270). We cannot exclude the possibility that CSHI 
constantly saturated the 11ȕ-HSD2 enzyme, resulting in increased excretion of free 
cortisol in the urine.  
Effects on carbohydrate and lipid metabolism 
We have shown that with OHC there is a progressive unphysiological decrease in late 
night glucose levels, probably resulting from the lack of cortisol. Although we did not 
identify any hypoglycaemias, other studies have reported the occurrence of nighttime 
hypoglycaemia in AD (271). With CSHI, the lowest glucose levels were observed at h 
03:00 as in healthy people, and a further decrease in glucose levels was avoided. Only 
small between-treatment differences were found in insulin levels. Theoretically, 
glucose levels seemed more physiological with CSHI than with OHC, but the clinical 
benefit of increasing glucose levels within the reference range in a non-diabetic AD 
patient with no hypoglycaemia is uncertain. Our results do however suggest that 
mimicking the late night cortisol surge with CSHI or modified release hydrocortisone 
can be beneficial in AD patients with concomitant diabetes mellitus. Conversely, 
during daytime the glucose and insulin levels tended to be higher with OHC than with 
CSHI, but these differences were not statistically significant. OHC doses were 
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significantly reduced from pre-trial doses, possibly contributing to the lack of 
between-treatment difference in daytime glucose and insulin levels. In the current 
study, reassuringly, we found no between-treatment difference in M-value with 
euglucaemic hyperinsulinemic clamp despite the between-treatment difference in 
hydrocortisone dose.  
al-Shoumer and co-authors found that in addition to low glucose levels during the 
night, patients with hypopituitarism on conventional GC replacement also had low 
concentrations of other metabolic fuels such as non-esterified fatty acids (NEFA) and 
3-hydroxybutyrate (272). In another study from the same group, fasting total 
cholesterol, LDL, triglycerides and apolipoprotein B were elevated in patients 
compared to controls, and the AUC24h for cholesterol and triglycerides were 
significantly higher in patients than in controls (272). Furthermore, they later 
performed a small study in patients with hypopituitarism replaced with GCs; here, 
they showed that GH replacement increased nighttime NEFA levels, but had no effect 
on glucose levels (273). In line with their findings, in our study fasting levels of 
cholesterol, LDL, HDL and triglycerides did not differ between CSHI and OHC, and 
we found no difference in nighttime triglyceride levels, suggesting that mimicking the 
physiological nighttime cortisol surge does not influence the lipid levels. Possibly, the 
total GC dose has a higher impact on lipids than restoring the circadian cortisol 
rhythm, as a daily dose of more than 20 mg/d increases BMI, total cholesterol, LDL 
and triglycerides in patients with hypopituitarism (138). The daily hydrocortisone 
equivalent dose in our trial was relatively low for both CSHI and OHC.  
Effects on bone markers 
When evaluating effects on bone metabolism in our study, it is a challenge that patient 
number was low and the study relatively short. OHC produced an increase in P1NP 
probably related to the reduction of hydrocortisone dose, and no alteration in CTX-1. 
This suggests that a small reduction of the conventional daily GC replacement dose 
has beneficial effects on bone formation without altering bone resorption. 
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Surprisingly, CSHI resulted in a reduction of P1NP despite the dose reduction, while 
CTX-1 decreased; possibly indicating an overall reduced bone turnover with CSHI.  
Since only CTX-1 and P1NP were measured, we cannot relate our findings to other 
relevant measures such as levels of calcium, vitamin D, parathyroid hormone or 
osteocalcin. Importantly, the changes in CTX-1 and P1NP were small for both CSHI 
and OHC, and mean levels were within reference ranges for both treatments. 
Furthermore, as the intra-individual variability is high for both P1NP and CTX-1, the 
least significant change for both has been calculated to around 30%, suggesting that 
the changes in P1NP and CTX-1 observed in our trial may not be clinically relevant 
(274, 275). Also, bone resorption markers such as CTX-1 display a circadian rhythm 
with a peak during the night followed by decreasing levels towards a nadir in the 
middle of the day (276, 277). Likewise, a similar circadian rhythm with lower 
amplitude has been described for bone formation markers, especially for osteocalcin 
and P1CP (278). Some authors have suggested that the circadian cortisol rhythm is 
implicated in the circadian variation in bone metabolism (279), which could imply 
that the decrease in P1NP with CSHI in our study may result from restoring the 
circadian cortisol rhythm. In contrast, a Danish study examined circadian levels of 
bone markers during OHC replacement in seven patients with SAI and four with AD. 
Here, the daily OHC doses (20-30 mg) were divided into four equal doses 
administered at h 06:00, 12:00, 18:00 and 24:00; although this distorted the circadian 
cortisol rhythm, the circadian rhythm was maintained for bone resorption markers and 
the bone formation markers osteocalcin and PICP (280). This suggests that the 
cortisol rhythm is of little importance in the regulation of circadian bone metabolism. 
Alternatively, the decrease in P1NP with CSHI could imply that continuous delivery 
of hydrocortisone inhibits bone formation. Osteoblasts contain glucocorticoid 
receptors (279), which may respond differently to a continuous hydrocortisone 
delivery as opposed to the ultradian delivery in healthy people (24). The higher 
cortisol bioavailability seen with CSHI could possibly also contribute.  
Although changes in bone markers were small and within the normal reference range, 
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our results suggest that future studies on circadian cortisol delivery should include 
circadian measurement of bone markers. CSHI provides an opportunity to study the 
relationship between the circadian rhythms of cortisol and bone markers.   
HRQoL 
This study did not have statistical power to reach firm conclusions on HRQoL effects, 
but the observed improvement of AddiQoL scores suggests that CSHI diminishes 
fatigue and improves HRQoL in AD. Importantly, a reduction of GCs from the pre-
trial doses both in the CSHI and OHC arms did not adversely affect HRQoL. Thus, 
our results suggest that replicating the circadian cortisol pattern by CSHI might 
improve HRQoL. However, since HRQoL scores are subjective, results have to be 
interpreted with caution due to the un-blinded study design.  
The HRQoL results were not as striking as in the pilot trial, probably because this trial 
recruited unselected patients whereas the patients in the pilot trial were selected 
because they had poor functioning. The SF-36 scores at the start of each treatment 
arm in our study were a little higher than previously published SF-36 scores in AD 
(87, 88, 128). Also, the majority of the participants were full-time workers (60.6%); 
only 12.1% did not work. Only 21% did not engage in physical activity, whereas 55% 
exercised more than 3h per week. Taken together, this indicates that the randomised 
patients were relatively healthy. Nevertheless, we found that the SF-36 Physical 
Function score was better with CSHI than with OHC. The PGWB scores at baseline 
were very similar to the Norwegian and Swedish results in the AddiQoL validation 
study (Paper 2). There was a significant trend towards improvement of the PGWB 
total score during CSHI treatment, but no significant between-treatment difference. 
The complexity of CSHI in combination with all the security precautions in the trial 
could possibly compromise HRQoL and render the patients more anxious and 
worried. Therefore, it was reassuring to find that anxiety levels did not increase, in 
fact, they tended to decrease on CSHI.  
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A better estimate of the responsiveness of a questionnaire can be obtained by 
examining the ratio of the mean change in HRQoL score after treatment to the 
variability in score at baseline (269). For the AddiQoL scores obtained in the clinical 
trial this ratio is promising, indicating that the sample size needed to detect statistical 
significant differences over time is lower with the AddiQoL, and the responsiveness 
better, than with the two generic questionnaires. As mentioned above, the clinical trial 
was not designed for testing AddiQoL responsiveness; hence, future studies are 
needed for clarification. 
Theoretically, the between-treatment differences found in HRQoL levels could be due 
to the between-treatment differences in GC doses. However, there is no evidence 
indicating that higher glucocorticoid doses increase HRQoL in AD; to the contrary, 
studies have suggested that supra-physiological GC doses are associated with 
decreased HRQoL (88, 197). Furthermore, increasing the serum cortisol AUC by 
more frequent dosage of the same total daily dose did not improve HRQoL levels in 
another study (198).  
Sleep 
Associations between the circadian cortisol rhythm and sleep architecture are well 
known (29). Actigraphy is a good tool for evaluating circadian rhythm disorders 
(281), but cannot give information about sleep architecture, i.e., the length and 
distribution of sleep stages. Hence, information about whether restoring circadian 
rhythm improves sleep architecture in AD could be lost by our choice of method. 
However, our results suggest that overall, sleeping problems are a minor issue in AD, 
and we found no objective sleep benefit of replicating the circadian cortisol rhythm 
compared with conventional OHC. The shorter sleep time reported with CSHI could 
suggest that increasing late night cortisol results in more alertness in the morning, but 
given the subjective nature of these data in combination with the non-blinded study 
design, it seems prudent to rely more on the objective actigraphy recordings. Future 
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studies in circadian replacement therapy should include polysomnography, which is 
the gold standard of sleep evaluation.  
Methodological considerations 
Initially, we aimed for a double-blind study design. We were, however, unable to find 
a manufacturer willing to produce a placebo for CSHI, which may not be surprising 
since Solu-Cortef is an Act-O-Vial (powder and fluid to be mixed by the patient); 
hence the powder, the fluid and the mixed product would have to look identical to the 
active drug. In addition the product would have to be approved for subcutaneous use. 
Even though saline do not have an identical appearance to Solu-Cortef, we also 
considered using isotonic saline as placebo. Because mixed Solu-Cortef Act-o-Vial is 
approved for use within 3 days only, this implied shipping of study drugs to each 
patient’s home every three days, which proved logistically too challenging. As longer 
shelf-life has been reported for hydrocortisone (282), we also tested the stability of 
pre-mixed Solu-Cortef at room temperature versus lower temperatures, to see if it 
could be possible to ship the study drug refrigerated and less frequently without 
compromising safety. Premixed Solu-Cortef samples were stored cold and in room 
temperature, and then subjected to measurement of Solu-Cortef concentration (LC-
MSMS), the appearance of degrading products (LC-MSMS scan), pH measurement 
and a visual inspection for colour and precipitation. The preliminary results showed 
that both the concentration of hydrocortisone and pH were stable for seven days when 
refrigerated, but the concentration declined somewhat in room temperature. Visual 
inspections did not differ, and we did not identify any degrading products except 
hydrocortisone succinate and sodium cortisol. However, even weekly shipment of 
refrigerated solutions would have been hampered by logistics, because we knew that 
some of the participants would live far from the hospital, otherwise the number of 
participants would be dramatically reduced. We therefore finally decided to choose an 
un-blinded study design.  
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The open-label crossover design of the clinical trial implies some important 
limitations to the interpretation of the treatment effects. Most likely, the primary 
outcome ACTH and the metabolic parameters are not severely affected by placebo 
effects; however, caution is required when interpreting effects on subjective HRQoL 
and sleep scores.  
Future perspectives 
In conclusion, we demonstrate in a controlled fashion that CSHI is a safe and more 
physiological replacement therapy than OHC, and might become a treatment option 
for selected AD patients. CSHI can be an option for capable AD patients who are 
symptomatic despite up to date conventional treatment with OHC or oral cortisone in 
combination with optimal fludrocortisones dosage. We know from clinical practice 
and personal communication that long-term CSHI has already been applied in several 
selected AD patients world-wide. Also, a few cases have been reported in the 
literature of patients with congenital adrenal hyperplasia successfully treated with 
CSHI during adolescence (283, 284). That patient group is especially suited for more 
physiological GC replacement, as the lack of cortisol during the night with 
conventional treatment results also result in high androgen levels (217). Our results 
also suggest that with CSHI the nighttime decrease in blood glucose levels in patients 
with AD can be avoided, which might be advantageous for AD patients with 
concomitant diabetes mellitus.  Because the oral route is bypassed, CSHI also has the 
potential to reduce the risk of acute adrenal crisis precipitated by vomiting and 
diarrhoea, and may become a treatment option for patients with malabsorption.  
Patients who are functioning well with OHC may perceive CSHI as complicated and 
disturbing, whereas patients with poor functioning may experience significant gain 
and readily accept CSHI treatment. On the other hand, the pumps are getting smaller 
and easier to manage, and due to the development in our society in general patients 
are less afraid of, and more accustomed to, the use of technology in their daily lives. 
In our trial, most patients managed the pump treatment well, without major problems.  
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Five of the 18 Norwegian patients in this trial insisted on continuing CSHI treatment 
at the end of our trial; in Sweden no one continued, as this was not given as an option.  
Another argument against pump treatment is that it is more expensive than 
conventional oral treatment; although not necessarily so when compared to modified-
release hydrocortisone. Hopefully, with improvement of pump technology, the cost of 
such treatment can be reduced, making CSHI an affordable choice for a larger group 
in the future.  
Furthermore, when now proved feasible and safe we believe that CSHI is a versatile 
method for further refinement and studies of the GC replacement therapy. While our 
results have shown that CSHI can restore the physiological circadian variation in 
cortisol levels, resulting in normalisation of ACTH levels and possibly HRQoL 
improvement. However, the ultradian rhythm cannot be replicated with the current 
dosing (6). The rapidly developing pump technology in combination with new 
knowledge on cortisol rhythms enables us to further refine the therapy. It may become 
possible to mimic the ultradian rhythm, by programming the pump to deliver pulses of 
hydrocortisone superimposed on a circadian delivery. Future CSHI trials should aim 
at replicating the full ultradian rhythm, which could possibly further improve outcome 
for AD patients. 
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7. LIMITATIONS 
The AddiQoL 
Although disease-specific questionnaires usually are more sensitive for detecting 
changes in HRQoL scores over time, testing for such responsiveness was not included 
in the AddiQoL validation study. Even though the AddiQoL detected significant 
HRQoL improvement with CSHI during the clinical trial, our results should 
preferably be confirmed by other interventional trials. However, formal testing of 
AddiQoL responsiveness is hampered by the lack of a clinical relevant correlate, as 
no such objective suitable test exists for AD.  
Also, the clinical utility of the AddiQoL when following individual patients could 
possibly be improved. This implies relating individual AddiQoL scores to that of 
other groups of patients in order to pinpoint an individual score as good or bad, 
aiming to identify patients with poor functioning in need of intervention. The 
published scores from the validation study were scores calculated from the person 
location score, hence scored range from zero to 100, making comparisons more 
difficult. Publishing the percentiles of AddiQoL raw scores ranging from 30 to 120 
from individual countries might aid interpretation of scores in individual patients. 
The clinical trial 
Rejecting the null hypothesis when it is in fact true is called a statistical type 1 error. 
Here, one null hypothesis is that HRQoL scores do not differ between CSHI and 
OHC. In that case, a type 1 error would translate to finding a significantly improved 
HRQoL on CSHI, when in fact the observed improvements in HRQoL score are a 
result of chance. When examining HRQoL, most studies use multiple questionnaires 
each containing multiple subscales. As multiple testing increases the risk of Type 1 
error, the significance level should preferably be lowered to minimize the risk. 
Pretrial, the statistical power analyses where performed assuming significant 
difference equals p <0.05. In retrospect, we acknowledge that a more conservative 
approach (p<0.01) might be warranted due to statistical testing of multiple variables, 
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to reduce the risk of type 1 error. If we this way retrospectively consider our results, 
the between-treatment differences in HRQoL scores is only borderline significant 
(AddiQoL p for interaction = 0.012). However, there is still a significant HRQoL 
improvement with CSHI, as evaluated by p for trend for the AddiQoL, the AddiQoL 
short version and the PGWB vitality score. 
On the other hand, endorsing the null hypothesis when it is in fact false is called a 
type 2 error. In our study this translates to rejecting effects that were not statistically 
significant, because the sample size was too small, i.e., the statistical power too low. 
When studying a rare disease like AD, there is always a risk of making a type 2 error 
because the sample size is small. Of course, we would have preferred a higher sample 
number in this trial to reduce the risk of statistical errors.  
Anyway, the open-labelled study design is most likely a more important limitation for 
the interpretation of the HRQoL and sleep outcomes than the p-values. Firm 
conclusions cannot be reached without blinding. 
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8. CONCLUSIONS  
• We have successfully developed the disease-specific quality-of-life 
questionnaire AddiQoL to improve evaluation of HRQoL in AD patients both 
in clinical trials and in clinical practice. 
• The original 36-item AddiQoL UK was translated to five other European 
languages and further validated resulting in a revised 30-item version, tested 
on 615 European AD patients; AddiQoL proved valid and reliable, with a good 
targeting to AD patients. 
• AddiQoL demonstrated a superior ability to detected HRQoL improvement 
when compared with the generic questionnaires SF-36 and PGWB, but larger 
studies testing the AddiQoL’s responsiveness are needed. 
• CSHI reinstated the circadian cortisol rhythm, resulting in near normal ACTH 
levels in sharp contrast to the typical daytime cortisol peaks and troughs and 
elevated morning ACTH seen on OHC treatment. 
• Whereas OHC yielded major alterations in the pattern of urinary GC 
metabolites and estimated metabolic enzyme activities, CSHI restored GC 
metabolism closer to normal; urinary excretion of cortisol and cortisone was 
high with CSHI, indicating a higher bioavailability for parenteral 
administration.  
• HRQoL improved with CSHI, whereas no HRQoL benefit was seen with 
OHC, despite individually adjusted doses and a reduction of the daily 
hydrocortisone doses. 
• CSHI did not alter sleep when compared to OHC. 
• Restoration of the nighttime cortisol surge with CSHI prevented the gradual 
nighttime decline in glucose levels seen with OHC, without compromising 
insulin sensitivity.  
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